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ABSTRACT: POLYMERIC NANOCARRIERS DELIVERING ANTICANCER
AGENTS FOR THE TREATMENT OF CHEMORESISTANT PROSTATE
CANCER AND LUNG METASTATIC MELANOMA
Ruinan Yang, Ph.D.
University of Nebraska, 2018
Supervisor: Ram I. Mahato, Ph.D.
The aims of this thesis is to first develop novel combination chemotherapies
of two anticancer agents and their appropriate drug delivery platforms to treat
chemoresistant prostate cancer, and second develop a polymeric conjugate of a
biodegradable polymer and novel tubulin destabilizer to treat lung metastatic
melanoma.
In Chapter 1, a general introduction of polymeric nanocarriers including
polymeric micelles and polymer drug conjugates for cancer therapy was given. In
Chapter 2, we described a combination therapy of paclitaxel (PTX) polymer
conjugate and cyclopamine (CYP) polymer conjugate, which had the potential to
treat chemoresistant prostate cancer. We first synthesized mPEG-b-PCC-g-PTXg-DC (P-PTX) and mPEG-b-PCC-g-CYP-g-DC (P-CYP) polymer-drug conjugates,
which they self-assembled into micelles. The combination of P-PTX and P-CYP
alleviated PTX resistance and suppressed tumor colony formation. Further,
combination therapy inhibited Hedgehog (Hh) signaling and upregulated tumor
suppressor miRNAs. We established orthotopic prostate tumor in nude mice and
there was significant tumor growth inhibition in the group treated with the
combination therapy of P-PTX and P-CYP compared with monotherapy. In
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Chapter 3, we designed a novel microtubule destabilizer QW-296 and combined
it with a newly synthesized Hh signaling inhibitor MDB5 to treat taxane-resistant
prostate cancer. The combination of QW-296 and MDB5 exhibited stronger
anticancer activity towards chemoresistant prostate cancer cells than single drug
treatment, and the results revealed that they synergistically worked together via
distinct but complementary mechanisms. To improve the translation and promote
therapeutic efficacy of the two novel anticancer agents, we synthesized an
amphiphilic copolymer mPEG-p(TMC-MBC) that could self-assemble into
polymeric micelles and encapsulate two hydrophobic drugs with high drug loading.
We established a model of orthotopic prostate tumor in nude mice to evaluate in
vivo efficacy of QW-296, MDB5 and their combination. The results confirmed that
combination of QW-296 and MDB5 in micelles showed maximum inhibition of
tumor growth compared with monotherapy or combination therapy in co-solvent.
In Chapter 4, we introduced a new microtubule destabilizer SMART-OH and its
polymer-drug conjugate, methoxy-poly (ethylene glycol)-block-poly (2-methyl-2carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (abbreviated as PSMART). Similar to its parent drug, P-SMART showed significant anticancer
activity against melanoma cells in cytotoxicity, colony formation, and cell invasion
studies. In addition, P-SMART treatment led to cell cycle arrest at G2/M phase and
cell accumulation in sub-G1 phase. We established a model of metastatic
melanoma to the lung in C57/BL6 albino mice to determine in vivo efficacy of PSMART and SMART-OH at the dose of 20 mg/kg. P-SMART treatment resulted in
significant inhibition of tumor growth and prolonged mouse median survival. In the
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end, Chapter 5 summarized the featured results of this thesis and gave some
suggestions for future studies.
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CHAPTER 1 INTRODUCTION

1.1 POLYMERIC NANOCARRIERS FOR CANCER TREATMENT
Even though the overall cancer death rate has dropped by more than 20%
over two decades, cancer accounts for the most common cause of death in the
United States. Approximately, there are 439 new cases of cancer and 163 cancer
deaths every 100,000 men and women per year. Globally, there were 14.1 million
new cases and 8.2 million cancer-related deaths in 2012. These statistics indicate
that progresses in preclinical research of cancer biology have slowly been
translated into actual improvement in cancer therapy and much work still remains,
which encourages more emerging collaborations among oncologists, cancer
biologists, biomaterial scientists and biomedical engineers. Among various clinical
therapies for cancer treatment, chemotherapy is still the mainstay, however, the
inefficiency and side effects of chemotherapy associated with conventional
formulations of anticancer small molecules are urgently needed to overcome.
Many chemotherapeutic drugs have poor aqueous solubility, which requires
appropriate formulation to assist solubilization when intravenous administration
needed. Cremophor EL, for example, is the formulation vehicle for paclitaxel and
also known to exert a range of side effects even including anaphylactoid
hypersensitivity and nephrotoxicity [1]. Off-target to the site of interest and wide
biodistribution via bloodstream of anticancer agents also attribute to inefficiency of
chemotherapy, suggesting the ideal formulation should have the capability to
deliver and release drugs precisely at the target sites in a sustained and controlled
manner.
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Nanomedicines have been no doubt gaining tremendous recognition as
indispensable tools to assist and boost chemotherapies and other traditional
cancer therapies. They are designed to much elevate water solubility of given
drugs, provide selective delivery of anticancer agents to target tumor site, and has
the potential to alter the pharmacokinetics of those drugs leading to extended
blood circulation time and accumulation at the site of action. A variety of innovative
nano-delivery platforms such as polymeric nanocarriers, liposomes, dendrimers,
nano-hydrogels have been developed and applied to deliver specific anticancer
agents including small-molecular-weight drugs, proteins, peptides and genes.
Synthetic polymer-based nanocarriers have been extensively investigated among
a variety of nanocarrier systems due to their amphiphilic characters and chemical
versatility [2]. This chapter will mainly focus on the introduction and recent research
progress of polymeric micelles and polymer-drug conjugates.
1.2 POLYMERIC MICELLES
Polymeric micelles, which were initially introduced by Ringsdorf in 1984 [3],
are assembled by amphiphilic block copolymers in aqueous milieu. They are
characterized by the core-shell architecture, where hydrophobic composition are
segregated from hydrophilic exterior to form an inner core. Core segregation from
aqueous solvent is the major driving force for micelle formation along with a variety
of intermolecular forces such as hydrophobic interaction, electrostatic interaction,
and hydrogen bonding [4-13]. Several advantages of polymeric micelles make
them favorable drug carriers compared with conventional dosage forms. First,
polymeric micelles have a size range from several tens to a hundred of nanometers
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with a narrow distribution, which can help micelles avoid from rapid renal clearance
and retain in the target tissue with an enhanced permeation retention (EPR) effect
involved [14]. Second, the amphiphilic character of micelles protects hydrophobic
drugs in of the core from degradation of hydrolytic enzymes, and accounts for
relatively prolonged retention time in blood circulation. It has been reported that
nanoformulations with hydrophobic outer surfaces tend to be easily taken up by
reticuloendothelial system (RES) or mononuclear phagocyte system (e.g.
monocytes and macrophages) [15,16], whereas those with hydrophilic surfaces
could minimize protein adsorption, prevent unwanted aggregation between
micelles, and show increased circulation time [17]. Furthermore, shell surface of
polymeric micelles can be decorated by a variety of functional groups facilitating
receptor-mediated drug delivery. Poly(ethylene glycol) (PEG) has been widely
used as hydrophilic backbone of polymeric micelles due to their biocompatible
hydrophilic nature and the stealth behavior resulting in reduced interaction with
plasma proteins and cell-surface proteins [18-20].
1.3 POLYMER-DRUG CONJUGATES
Polymer and anticancer drug conjugates have also drawn extensive
attention to researchers for cancer therapy from bench side to bedside. Generally,
the design of polymer conjugates is to chemically combine drug molecules to an
amphiphilic block polymer to form a macromolecular prodrug. Although, the
conjugated drug may lose some therapeutic activity in the form of the prodrug,
there are several advantages of the conjugates over corresponding parent drugs
such as less side effects, enhanced accumulation to site of interest and improved
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patient compliance, which makes polymer-drug conjugates have become a fastgrowing application in clinical studies. Similar with polymeric micelles, PEG is one
of the most common hydrophilic polymers to be selected as hydrophilic blocks,
because it has chemical flexibility of the chain in favor of subsequent conjugation
and it is approved by FDA for human use [21]. However, PEG only has two terminal
groups able to conjugate with drugs, thus the selection of hydrophobic segment
for PEG copolymer are mainly based on its drug conjugating capacity that enables
reaction with reactive groups on the drug molecule. A variety of monomers that
have reactive groups such as OH, COOH, NH2, CH=CH2, C≡CH can be introduced
the polymer chains [22-27]. The linker or the spacer between polymer and small
molecule are supposed to be relatively stable during transport in physiological
condition and hydrolysed at the site of target. In contrast with PEG, N-(2hydroxypropyl)-methacrylamide copolymers (HPMA), another widely used
hydrophilic block, has multiple reactive groups and can be simultaneously
functionalized with therapeutic agents, targeting moieties as well as imaging
moieties. Typically, a lysosomally degradable peptidyl Gly-Phe-Leu-Gly is most
commonly used linker for HPMA drug conjugation.
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CHAPTER 2 COMBINATION THERAPY OF PACLITAXEL AND
CYCLOPAMINE POLYMER-DRUG CONJUGATES TO TREAT
ADVANCED PROSTATE CANCER1

2.1 INTRODUCTION
Prostate cancer is the second leading cause of cancer-related deaths in
American men. Although androgen deprivation therapy (or androgen suppression
therapy) is effective in treating prostate cancer in early stage [28], shrunken tumors
often become androgen-independent at 18-24 months post-treatment [29], leading
to aggressive and metastatic forms of prostate cancer, also known as hormone
refractory prostate cancer (HRPC). Taxane (docetaxel and paclitaxel (PTX)) is one
of the standard therapies for HRPC [30]. While these anticancer agents have
shown significant efficacy at the initial stage of chemotherapy, the long-term
efficacy is limited and patients will suffer from relapse owing to the development of
chemoresistance [31-35]. Therefore, there is an urgent need to improve the longterm efficacy of current chemotherapy.
Hedgehog (Hh) signaling influences the initiation and progression of cancer
and is needed for regeneration of prostate epithelium through crosstalk with
androgen signaling [36-39]. Therefore, the inhibition of Hh pathway has the
potential to induce anti-proliferative and apoptotic effect on prostate cancer cells.
Furthermore, Hh signaling involves in the initiation and development of cancer

1

R. Yang, G. Mondal, D. Wen, R.I. Mahato, Combination therapy of paclitaxel and cyclopamine
polymer-drug conjugates to treat advanced prostate cancer, Nanomedicine. (2016)
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stem cells (CSCs), which are a distinct subset of cancer cells with selfrenewal/differentiation and tumorigenic potentials [40-42]. Thus, depleting CSCs
at the early stage is essential to inhibit tumor growth and metastasis.
Cyclopamine (CYP), a naturally occurring antagonist of Hh signaling, binds
to cell surface receptor smoothened (SMO) resulting in suppression of SMO
activity and inhibition of Hh signaling pathway [43,44]. CYP has shown to inhibit
the proliferation of DU145, PC3 and 22RV1 cells and reduce tumor growth in mice
[45,46]. In this regard, a combination therapy of PTX and CYP could have
synergistic therapeutic efficacy of treating advanced prostate cancer and also lay
the foundation for promising chemotherapy. However, these drugs are highly
hydrophobic, which require an appropriate drug delivery system, such as
liposomes, nanoparticles and micelles, for their formulation and delivery to the
tumor after systemic administration. Polymer-drug conjugates acquire wide
attention and some of them are undergoing clinical trials or ready to reach the
market [47-52]. Unlike physically drug encapsulated liposomes, nanoparticles and
micelles, polymer-drug conjugates prevent premature drug release and undesired
toxicities as covalently linked polymer-drug conjugates are more stable in the
circulation and release drugs in a controlled manner at the tumor site with
therapeutically effective concentration. Moreover, covalent drug conjugation to
polymers achieves enhanced drug payload compared to physically encapsulated
micelles or nanoparticles. Additionally the nano-size ensures preferential
accumulation of these conjugates in tumor cells via the enhanced permeability and
retention (EPR) effect [53].
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In our previous studies [54], we synthesized poly (ethylene glycol)-blockpoly (2-methyl-2-carboxyl-propylene carbonate) (mPEG-b-PCC) for drug delivery.
In this study, we conjugated PTX and CYP to the carboxyl pendant groups of
mPEG-b-PCC (Mw: mPEG 5000 Da, PCC 4480 Da, 28 units). Besides PTX and
CYP, the final polymeric conjugates consist of three components, biocompatible
PEG blocks, a biodegradable polycarbonate backbone and dodecanol (DC) lipid
chains. PEG ensures the stealth properties of polymeric conjugates and the
polycarbonate backbone has low toxicity since its degradation products are CO2
and alcohol. In addition, DC can increase requisite hydrophobicity and thus assist
in self-assembly into nano-sized micelles. This conjugation strategy has the
potential to effectively deliver drugs to tumors after systemic administration and
treat orthotopically implanted prostate cancer in mice by killing both bulk tumor
cells and CSCs.
2.2 METHODS
2.2.1 Synthesis of mPEG-b-PCC-g-PTX-g-DC (P-PTX)
Synthesis scheme of polymer-drug conjugates is illustrated in Figure 1.
Monomer 2-methyl-2-benzyloxycarbonyl-propylene carbonate and its copolymer
with mPEG (mPEG-b-PBC) were synthesized by ring opening polymerization
followed by hydrogenation to obtain the copolymer containing carboxyl pendent
groups (mPEG-b-PCC) as previously described. PTX and DC were conjugated to
the carboxyl groups of mPEG-b-PCC polymer using carbodiimide coupling.
mPEG-b-PCC (75 mg, 0.0079 mmol) was dissolved in anhydrous dichloromethane
(DCM) followed by addition of PTX (54 mg, 0.063 mmol), DCC (65 mg, 0.31 mmol),
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DMAP (29 mg, 0.24 mmol). The reaction was stirred for three days under nitrogen
atmosphere at 4°C and then DC (23.5 mg, 0.12 mmol) was added and the reaction
was allowed to proceed for another two days (Figure 1A). Crude product was
purified by precipitation in large excess of diethyl ether and then by dialysis against
hanol using a regenerated cellulose membrane with 7K MWCO.
2.2.2 Synthesis of mPEG-b-PCC-g-CYP-g-DC (P-CYP)
Synthesis of Boc-β-Ala-TT.

Boc-β-Ala-OH (94.6mg, 0.5 mmol), 2-

mercaptothiazoline (59.6 mg, 0.5 mmol) and DMAP (61.1 mg, 0.5 mmol) were
dissolved in DCM under nitrogen protection. The solution was first stirred for 5 min
-10 °C followed by adding EDCI (95.9 mg, 0.5 mmol) and the solution was stirred
at -10 °C for 3 h and another 14 h at room temperature. After reaction, 40 mL DCM
was added and the solution was washed with NaHCO3 aq. (0.1 M), HCl (0.1 M)
and then NaCl aq. The organic layer was dried by Na2SO4 and the crude product
was purified by column chromatography (silica gel 60 Å, 200-400 mesh, EtOAc:
CH3OH 15: 1) and then recrystallized from DCM to give yellow powder. The
structure was confirmed by 1H-NMR spectroscopy.
Synthesis of Boc-β-Ala-CYP. Boc-β-Ala-TT (107 mg, 0.37 mmol) and CYP
(76 mg, 0.18 mmol) were dissolved in pyridine under nitrogen atmosphere. The
solution was stirred at 50 °C for 28 h and then the solvent was removed by rotary
evaporation. The crude product was purified by column chromatography (silica gel
60 Å, 70-230 mesh, EtOAc: Hexane 7:3) to give solid of Boc-β-Ala-CYP in 75 %
yield. The structure was confirmed by 1H NMR spectroscopy and LC-MS.
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Synthesis of NH2-β-Ala-CYP. Boc-β-Ala-CYP was dissolved in anhydrous
DCM (3 mL) and TFA (3 mL) was added at 0 °C. The resulting solution was left
stirring overnight to ensure complete Boc removal. Excess TFA was removed by
nitrogen flushing. The resulting compound was dissolved in chloroform (15 mL)
and washed with aqueous saturated NaHCO3 (3 x 20 mL) and brine (1 x 20 mL).
The organic layer was dried over anhydrous sodium sulfate and filtered. NH2-βAla-CYP was obtained after the solvent was removed by rotary evaporation. The
structure was confirmed by 1H NMR spectroscopy and LC-MS.
Synthesis of P-CYP. mPEG-b-PCC (123 mg, 0.013 mmol) was dissolved in
anhydrous DCM followed by the addition of NH2-β-Ala-CYP (50 mg, 0.10 mmol),
EDCl (50 mg, 0.25mmol), HOBt (35 mg, 0.25 mmol). The reaction was stirred for
two days under nitrogen atmosphere at the room temperature. Then, DC (48.3 mg,
0.25 mmol) was added and the reaction was allowed to proceed for another two
days (Figure 1B). After completion of the reaction, crude product was purified by
precipitation in large excess of diethyl ether. The precipitate was then purified by
dialysis against ethanol using a regenerated cellulose membrane with 3,500
MWCO.
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Figure 1. Synthetic scheme of two polymer-drug conjugates. (A) mPEG-b-PCCg-PTX-g-DC (P-PTX) and (B) mPEG-b-PCC-g-CYP-g-DC (P-CYP).

2.2.3 Characterization of polymer-drug conjugates
1H

NMR spectra were recorded on a Bruker (500 MHz, T = 25 °C) using

DMSO-d6 as a solvent for P-PTX and Chloroform-d as a solvent for P-CYP in a
chemical shift range of 0-12 ppm.
2.2.4 Preparation and characterization of polymer-drug conjugate micelles
The film hydration method was used for preparing P-PTX and P-CYP
conjugate micelles. Briefly, 10 mg of P-PTX or P-CYP was dissolved in
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dichloromethane (DCM) and the solvent was evaporated under reduced pressure.
The resulting film was hydrated with 1 ml of phosphate buffered saline (PBS; pH
7.4) followed by sonication and filtration through 0.22 μm filter. Mean particle size
was measured by using a Zetasizer Nano ZS90 (Malvern, Worcestershire, UK) at
a scattering angle of 173°. A total of 12 measurements were taken per sample with
a time span of 10 s. Particle size distribution was reported as the mean ± SEM. of
three independent samples. Critical micelle concentration (CMC) of P-PTX and PCYP was determined using pyrene as a hydrophobic fluorescent probe as
described previously [54].
PTX or CYP encapsulated micelles were also prepared by film hydration
method. Briefly, 1 mg of PTX or CYP and 9 mg of poly(ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate-graft dodecanol) (mPEG-b-PCC-gDC) (units of DC is 22) were dissolved in chloroform. Solvent was evaporated
under vacuum and resulting film was hydrated in 1 mL of PBS followed by
sonication. Free drug was removed by centrifugation at 3,000 rpm for 5 min and
filtration using a 0.22 μm filter. To determine the drug loading, PTX or CYP loaded
micelles were dissolved in methanol and the concentration was measured by
HPLC. Drug loading was calculated using the following equation:
Drug loading (w/w %) = Weight of encapsulated drug /Total weight of
formulation X 100
2.2.5 In vitro stability of p-ptx and p-cyp micelles
To determine the stability of P-PTX and P-CYP conjugate micelles under
the physiological conditions, micelles with final concentration of 1 mg/ml were
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incubated with 45 mg/mL bovine serum albumin (BSA) at 37 °C with gentle
agitation. The particle size distribution of these formulations was measured by DLS.
2.2.6 In vitro drug release
The release of PTX from P-PTX and CYP from P-CYP was determined at
pH 5.3 and 7.4 as previously described [55]. Briefly, 1 mg of P-PTX or P-CYP was
re-suspended in 1 ml buffer solution (0.1 M acetic acetate, pH 5.3 or 0.1 M
phosphate buffer, pH 7.4) and diluted with methanol in a volume ratio of methanol:
aqueous solution (1:3, v/v). All samples were incubated at 37 ℃shaken at 100 rpm
for 0, 6, 12, 24, 48, 72, 96, 120 and 144 h and neutralized to pH 7.4 prior to HPLC
analysis
In vitro release of PTX or CYP from mPEG-b-PCC-g-DC was determined
by dialysis (7K MWCO) against 50 mL PBS containing 2% Tween 80 at pH 5.3
and 7.4 with gentle agitation. 1 mL samples were taken at regular time intervals
and replaced with fresh media. Drug concentration was measured by HPLC as
described for drug loading. (Waters HPLC system with 996 photodiode array
detector (Milford, MA, USA)). All experiments were performed in triplicate and the
data reported as the mean of three individual experiments. Micelles (final
concentration of 1 mg/ml) were incubated with 45 mg/mL bovine serum albumin
(BSA) at 37 °C with gentle agitation. HPLC conditions for PTX detection: column:
Inertsil®ODS-3 (4.6 × 250 mm; 5 μm), mobile phase: 60:40 acetonitrile: water,
wavelength:

227

nm.

HPLC

conditions

for

CYP

detection:

column:

SymmetryShieldTM RP18 (4.6 x 250 mm; 5 μm), mobile phase: 30:70 acetonitrile:
water (0.1% trifluoroacetic acid); wavelength: 210 nm.
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2.2.7 Cell culture
The human metastatic prostate cancer cell lines DU145 and PC3 and their
PTX resistant versions DU145-TXR and PC3-TXR were a kind gift of Prof. Evan T.
Keller of the University of Michigan. DU145-TXR cells were cultured in DMEM
medium supplemented with 10% FBS and 1% penicillin/streptomycin. PC3-TXR
and PC3-luc-GFP cells were cultured in F-12K medium supplemented with 10%
FBS and 1% penicillin/streptomycin. All cell lines were grown and maintained in a
humidified incubator containing 5% CO2 at 37°C.
2.2.8 Cellular uptake of P-PTX
To determine the cellular uptake of polymer-drug conjugates, we
conjugated a fluorescent taxol derivative flutax-1 and dodecanol to copolymer
mPEG-b-PCC, treated PC3-TXR cells with 0.5 µM of this conjugate (P-flutax-1) for
12 h and the cellular internalization was observed under a fluorescent microscope
(Axio Vert.A1, Zeiss, USA) after washing the cells with PBS.
2.2.9 Cytotoxicity assay
DU145-TXR and PC3-TXR cells were used to determine the cell growth
inhibition ability of polymer-drug conjugates. Cells (5X103/well) were seeded in 96well plates and 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM PPTX and 10 µM P-CYP were added to different groups of wells after 24 h. Cell
viability was assessed by MTT assay after another one to three-day incubation.
The absorbance was measured at 560 nm and corrected for the cell debris by
subtracting absorbance at 630 nm. Cell viability was calculated using the following
formula:
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Cell viability (%) =Absorbance of test sample/Absorbance of control X 100
2.2.10 Colony formation assay
PC3-TXR cells were seeded into 6-well plates. Each well had 300 cells and
treatments of 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM P-PTX
and 10 µM P-CYP were added to the wells after 24 h. At 10 days post incubation,
colonies in each well were fixed by 10% formalin, stained with 0.5% crystal violet
solution and visualized under microscopy.
2.2.11 Real time RT-PCR of microRNA quantification
DU145-TXR and PC3-TXR cells were treated with 0.5 µM P-PTX, 10 µM PCYP and the mixture of 0.5 µM P-PTX, 10 µM P-CYP. After 72 h treatment, total
RNA was isolated from untreated and drug-treated cancer cells using miRNEasy
RNA isolation kit (Qiagen, Germany) following manufacturer’s instructions. Then,
200 ng of total RNA was converted to cDNA using miScript II RT Kit (Qiagen,
Germany). Diluted cDNA was mixed with universal primer and SYBR Green dye
and added to the wells of 96-well plates containing miScript primer. The plates
were run on a Roche Light Cycler 480® instrument and the expression of individual
miRNAs was analyzed using the obtained Ct values. For each of the selected
miRNA, a miScript PCR primer was purchased from Qiagen. This assay targets
only mature miRNAs, not their precursors. Untreated DU145-TXR and PC3-TXR
were used as the control to calculate the fold change in drug-treated cells,
respectively. As a normalizer, RNU6-1 was used as a housekeeping miRNA. The
following miRNA primers were used:
hsa-miR-29b-3p: UAGCACCAUUUGAAAUCAGUGUU
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hsa-miR-34a-5p: UGGCAGUGUCUUAGCUGGUUGU
hsa-miR-148a-3p: UCAGUGCACUACAGAACUUUGU
hsa-miR-200c-3p: UAAUACUGCCGGGUAAUGAUGGA
RNU6-1:
GUGCUCGCUUCGGCAGCACAUAUACUAAAAUUGGAACGAUACAGAGAAGA
UUAGCAUGGCCCCUGCGCAAGGAUGACACGCAAAUUCGUGAAGCGUUCC
AUAUUUU
2.2.12 Expression of miRNA target genes
We also determined the levels of several miRNA target genes, such as Gli1,
PTCH1, ZEB1, ZEB2, E-CAD, CD133 and NOTCH2 at 72 h post treatment of
DU145-TXR and PC3-TXR cells with the 0.5 µM P-PTX and 10 µM P-CYP. Then
total RNA were extracted using RNeasy RNA isolation kit (Qiagen, Germany),
reverse transcribed into cDNA template and amplified by real time RT-PCR using
SYBR Green dye universal master mix and the primers for different genes. GAPDH
was used as a housekeeping gene. The following primers were used:
CD133 forward primer: 5’AAGCATTGGCATCTTCTATGG-3’
CD133 reverse primer: 5’-AAGCACAGAGGGTCATTGAGA-3’
NOTCH2 forward primer: 5’-GGCATTAATCGCTACAGTTGTGTCT-3’
NOTCH2 reverse primer: 5’-GGAGGCACACTCATCAATGTCA-3’
Gli1 forward primer: 5’-TCCTACGGTCATCTCTCCATT-3’
Gli1 reverse primer: 5’-GCCAGGGAGCTTACATACATAC-3’
PTCH1 forward primer: 5’-TTGCTTGGGAGTCATTAACTG-3’
PTCH1 reverse primer: 5’-CCCACAATCAACTCCTCCTGCC-3’
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E-CAD forward primer: 5’-AAGAAGCTGGCTGACATGTACGGA-3’
E-CAD reverse primer: 5’-CCACCAGCAACGTGATTTCTGCAT-3’
ZEB1 forward primer: 5’-ATGCACAACCAAGTGCAGAAGAGC-3’
ZEB1 reverse primer: 5’-TTGCCTGGTTCAGGAGAAGATGGT-3’
ZEB2 forward primer: 5’-CTAACCCAAGGAGCAGGTAATC-3’
ZEB2 reverse primer: 5’-GGGAAGAACCCGTCTTGATATT-3’
GAPDH forward primer: 5’-GATTCCACCCATGGCAAATTC-3’
GAPDH reverse primer: 5’-GTCATGAGTCCTTCCACGATAC-3’
2.2.13 Evaluation in orthotopic prostate cancer bearing athymic nude mice
All animal experiments were performed in accordance with the NIH animal
use guidelines and protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Nebraska Medical Center (UNMC),
Omaha, NE. Orthotopic prostate tumors were established in 8 week-old male
6

athymic nude mice by injecting 1 × 10 PC3-luc-GFP cells suspended in 50 μl PBS
into dorsum of the prostate gland. Animals were randomly divided into four groups
of five animals per group when the radiance of tumor volume had reached 10 7.
Formulations were administered to these mice via the tail vein thrice a week for
two weeks. Group 1 was kept as the control and received normal saline, group 2
received 10 mg/kg P-PTX PBS solution (equivalent to free PTX), group 3 received
10 mg/kg P-CYP PBS solution (equivalent to free CYP) and group 4 received the
mixture of 10mg/kg P-PTX and 10mg/kg P-CYP PBS solution. Bioluminescent
radiance of tumor was measured every alternate day using IVIS ® Spectrum
imaging system (PerkinElmer Inc., MA). Body weight of these mice was recorded
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every alternate day. At the end of the animal study (i.e., day 24), mice were
sacrificed and tumors as well as vital organs (liver, spleen, kidney and heart) were
excised.
Five representative tumor tissues were collected per experimental group
and fixed with 10% buffered formalin for 24h. The fixed samples were embedded
in paraffin and thin sections of 4 μm were obtained and immunostained for cell
proliferation marker (Ki-67) and hematoxylin and eosin (H&E). To identify apoptotic
cells by fluorescein-12−dUTP labeling of fragmented DNA, DeadEnd fluorometric
TUNEL assay kit was used according to the manufacturer’s instructions. Tumor
sections were also counterstained with propidium iodide (PI) and imaged under a
fluorescence microscope.
2.2.14 Statistical analysis
Data are represented as means ± SEM. The statistical comparisons of the
experiments were performed by two-tailed Student’s test. P <0.05 was considered
statistically significant.
2.3 RESULTS
2.3.1 Synthesis and characterization of P-PTX and P-CYP
P-PTX was synthesized by direct carbodiimide coupling of PTX onto the
pendant carboxylic acid groups on the hydrophobic block of mPEG-b-PCC
copolymer and esterification took place preferentially at the 2’-hydroxyl group due
to its less steric hindrance. In

1H

NMR spectra of mPEG-b-PCC, protons

corresponding to −CH2−CH2−O− of PEG were observed at δ 3.4−3.6, and −CH2−
units of PCC δ 4.2−4.4 and −COOH were observed at δ 12−14 as reported earlier
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by our group. After conjugation of PTX to mPEG-b-PCC, protons corresponding to
PTX were all observed in 1H NMR spectra and PTX content in the conjugates was
determined to be 25.4±3.7% (w/w), as calculated from the peak intensities of all
phenyl proton signals from 7.3 to 8.4 ppm.
1H

NMR (500 MHz, DMSO-d6) spectra of mPEG-b-PCC-g-PTX-g-DC

showed peaks corresponding to PEG (−CH2−CH2−O) at δ3.5, PCC (−CO-O-CH2& CH3-C(CO)-CH2) at δ4.2 (m, 4H), CH3-(CH2)9- at δ0.9 (t, 3H), CH3-(CH2)9- at
δ1.2-1.45 (bs, 18H), CH3-(CH2)9-CH2 at δ1.5-1.8 (m, 4H), CH3-(CH2)9-CH2-CH2- at
δ4.02 (m, 2H), PTX-(CH3)2-C6H3 at δ 1.01 (t, 6H), PTX-C6H5-CH3 at δ 1.2 (t, 3H),
PTX-CH3-C6H3- at δ 1.8 (t, 3H), PTX-CH3-CO-O- at δ 2.3 (t, 3H), PTX-C6H5-CHNH- at δ4.78 (m, 1H), PTX-C6H5-CO-O-CH- at δ 4.79 (m, 1H), PTX-CHC2H2O- at
δ 5.34 (m, 2H), PTX-CH3-CO-O-CH- at δ 6.31 (m, 1H), PTX-C6H5- at δ7.3-8.4 (m,
15H), PTX-C6H5-CO-NH- at δ 9.0(m, 1H) (Figure 2A).
We have tried to conjugate CYP directly onto mPEG-b-PCC but we failed
to form amide bond between secondary amine of CYP and carboxyl group of
mPEG-b-PCC (data not shown). Therefore, CYP was conjugated onto mPEG-bPCC through a Boc-b-Ala linker because the secondary amine on CYP was not
easy to conjugate with carboxylic acid group on mPEG-b-PCC, thus after Bocremoval the primary amine on the linker made the conjugation of CYP to the
copolymer much easier. After conjugation of CYP to mPEG-b-PCC, protons
corresponding to CYP were observed in 1H NMR spectra and CYP content in the
conjugates were 14.5±1.6% (w/w) calculated from proton signal 1.7-2.4 ppm.
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1H

NMR (500 MHz, DMSO-d6) spectra of mPEG-b-PCC-g-CYP-g-DC

showed peaks corresponding to CYP-CH3-C4H3O-, CYP-CH3-C5H7N-, CYP-CH3C6H5- at δ1.01-1.3 (m, 9H), CYP-CH3-C-CH-CH-CH- at δ1.48-1.88 (m, 3H), CYPCH2-CH=C-CH2- at δ1.94-2.21 (m, 4H), CYP-O-C-CH-CH3 at δ 2.50 (m, 1H), CYPCH3-CH-CH2-N-CO-CH2- at δ 2.46 (m, 2H), CYP-CH3-CH-CH2-N-CO- at δ 3.68,
CYP-CH3-CH-CH2-N-CH- at δ 3.75 (m, 1H), CYP-CH3-C-CO-NH-CH2- at δ 8.01
(m, 1H) (Figure 2B).
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Figure 2. 1H NMR spectra of two polymer-drug conjugates. (A) P-PTX, (B)
P-CYP.
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2.3.2 Formulation characterization
High drug payload of these polymer-drug conjugates was observed by using
1H

NMR characterization (Figure 2): 25.40±3.70% (w/w) and 14.50±1.60% (w/w)

for PTX and CYP, respectively. Unlike polymer-drug conjugates, PTX and CYP
loadings in physically encapsulated micelles were 8.21±0.01% (w/w) and
5.36±0.07% (w/w), respectively.
P-PTX and P-CYP conjugate micelles were prepared by dissolving 10 mg
of P-PTX or P-CYP in dichloromethane followed by solvent evaporation under
reduced pressure to form a thin film, followed by hydration with 1 mL of PBS (pH
7.4). The mean particle sizes of P-PTX and P-CYP were 70.02 ± 0.22 nm (PDI
0.223) and 76.37 ± 0.15 nm (PDI 0.273), respectively. CMC values were 3 × 10−4
g/L for P-PTX and 4 × 10−4 g/L for P-CYP.
2.3.3 In vitro stability of P-PTX and P-CYP micelles
Within 48 hours, there was no significant change in the mean particle size
of P-PTX and P-CYP micelles before and after their incubation with BSA,
suggesting that plasma proteins were unlikely to affect the integrity of these
polymer-drug conjugate micelles (Figure 3).
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Figure 3. In vitro stability of P-PTX and P-CYP micelles in BSA after 12h, 24h
and 48h. (A) P-PTX, (B) P-CYP.

2.3.4 PH dependent drug release
In vitro drug release studies were carried out in PBS buffer with pH 7.4 and
acetate buffer with pH 5.3 to simulate drug release in blood and tumor cells. PPTX or P-CYP showed a slow but sustained release of PTX and CYP, respectively.
Due to the stability of conjugated PTX and CYP, there was no noticeable initial
burst release of these drugs at different pH 7.4 and 5.3. At neutral environment,
both ester and amide bonds were stable and no significant release of PTX and
CYP was observed. Since the liberation of free drugs required pH-dependent
cleavage of ester and amide linkages, the percentage of PTX and CYP released
from the conjugated micelles significantly increased as pH was decreased from
7.4 to 5.3. After six days, more than 25% of PTX and CYP was observed at pH 5.3,
while about 10% of PTX and CYP was released at pH 7.4 (Figure 4A).
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Figure 4. In vitro release of PTX from P-PTX and CYP from P-CYP at different
pH and with incubation of BSA. Drug concentrations from each time point were
measured by HPLC and drug release profiles were represented as the mean± SEM.

To better confirm the advantages of drug-conjugated micelles, we also
determined the release of PTX and CYP from physical-encapsulated micelles. As
expected, both PTX and CYP were released very fast. In the first 12 hours, burst
release of two drugs was observed and almost 60% of drugs were released after
24 hours (Figure 5). In addition, with incubation of BSA both PTX and CYP were
released from the conjugates very slowly as determined by HPLC (Figure 4B).
The mean particle sizes of P-PTX and P-CYP micelles before and after their
incubation with BSA were also monitored by DLS but there was no significant
change during 48 h (Figure 3). These results suggested that the conjugated
micelles were stable under physiologically simulating conditions.
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Figure 5. In vitro release of PTX and CYP from physically drug encapsulated
micelles at pH 7.4 and 5.3. (A) PTX, (B) CYP. Drug concentrations from each time
point were measured by HPLC and drug release profiles were represented as the
mean± SEM.

2.3.5 Cellular internalization
P-flutax-1 conjugate was efficiently taken up by the cells as evidenced by
green fluorescent positive cells (Figure 6).

Figure 6. Intracellular accumulation of P-flutax-1. PC3-TXR cells were incubated
with 0.5 µM P-flutax-1 for 12 h, and the intracellular accumulation of P-flutax-1 was
observed by Axio Vert.A1 Microscope.
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2.3.6 Cytotoxicity and colony formation assays
Cytotoxicity of 0.5 µM P-PTX, 10 µM P-CYP and the combination of 0.5 µM
P-PTX and 10 µM P-CYP was determined by incubating DU145-TXR and PC3TXR cells with these polymer-drug conjugate micelles for 24, 48 and 72 h. Due to
the slow release of these drugs from the polymer conjugates, combination therapy
of P-PTX and P-CYP had the highest cell-killing effect at 72 h compared to 24 or
48 h post incubation. Treatment with the combination formulation after 72 h killed
45.6% of DU145-TXR cells and 47.1% of PC3-TXR (Figure 7A-B). Both P-PTX
and P-CYP monotherapy failed to kill many cells at those doses, suggesting that
the combination formulation was quite effective in killing chemoresistant cancer
cells.
Tumorigenic potential of PC3-TXR cells was determined by colony
formation assay after treatment with P-PTX, P-CYP and their combination. Due to
the long-term treatment of polymer-drug conjugates, a large % of PTX and CYP
was released from the conjugates, resulting in significant anti-proliferative effect.
The number of colonies formed from untreated group was largest compared with
0.5 µM P-PTX, 10 µM P-CYP or the combination treated group, and the number
of colonies formed from combination treated group was significantly less compared
with other three groups (Figure 7C-D).
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Figure 7. Cytotoxicity and colony formation assay. Cytotoxicity assay of 0.5μM
P-PTX, 10µM P-CYP and their combination was determined in DU145-TXR and
PC3-TXR cells for 24, 48 and 72 h (A-B). For colony formation assay, 300 PC3-TXR
cells per well were seeded to 6-well culture plates. At 24h, drug formulations were
added and at 10 days, cell colonies were fixed, stained and counted *p<0.05,
**p<0.01 vs P-PTX+P-CYP (C-D).

2.3.7 Effect of combination therapy on miRNAs and their target genes
The effect of 10 µM P-CYP and its combination with 0.5 µM P-PTX on the
expression of miR-29b, miR-34a, miR-148a and miR-200c was determined in
DU145-TXR and PC3-TXR cells using real time RT-PCR. All these tumor
suppressor miRNAs were upregulated when treated with either 10 µM P-CYP or
its combination with 0.5 µM P-PTX (Figure 8). However, this effect was better
when the cells were treated with the combination therapy.
We also determined the levels of several known downstream targets of
these miRNAs and Hh signaling. There was downregulation of miR-200c target
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genes like ZEB-1 by 1.30 fold in PC3-TXR cells and ZEB-2 by 2.32 fold in DU145TXR cells, while the expression of another miR-200c target E-CAD was
upregulated in DU145-TXR cells by 4.75 fold and PC3-TXR cells by 3.62 fold
(Figure 8). miR-34a target gene CD133 was significantly downregulated and
NOTCH2 which is the target gene of miR-29b was also downregulated in DU145TXR cells by 2.0 fold and PC3-TXR cells by 7.69 fold. In addition, gene targets of
Hh signaling such as Gli1 and PTCH1 were regulated in a reverse pattern. While
Gli1 was highly downregulated in PC3-TXR after combination therapy, PTCH1 was
upregulated in DU145-TXR cells by 3.22 fold and PC3-TXR cells by 1.89 fold
indicating Hh signaling was inhibited when these cells were treated with the
mixture of P-PTX and P-CYP.
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Figure 8. Effect of combination therapy on tumor suppressor miRNA expression
and their target genes. DU145-TXR (A) and PC3-TXR (B) cells were used. To
determine miRNA expression, cells were treated with 10 µM P-CYP or combination
of 0.5µM P-PTX and 10µM P-CYP for 72 h. Total RNA was extracted using miRNEasy
RNA isolation kit, converted to cDNA and used for miScript primer assay for
determining miR-29b, miR-34a, miR-148a and miR-200c expression. Untreated cells
were used as the control for calculating fold change. RNU6-1 was used as a
housekeeping miRNA. To determine gene expression, cells were treated with
combination of 0.5µM P-PTX and 10µM P-CYP for 72 h. Following RNA extraction and
SYBR Green based real time RT-PCR using specific gene primers, Ct values were
calculated. Untreated cells were used to normalize gene expression and GAPDH was
used as a housekeeping gene.

2.3.8 Efficacy in orthotopic prostate tumor bearing mice
We established orthotopic prostate tumor in 8 weeks old male athymic nude
mice by injecting 1x106 PC3-luc-GFP cells. At day 7, all mice were imaged for
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luciferase bioluminescence to determine the tumor growth rate (Figure 9) and
mice whose bioluminescent radiance achieved 107 were randomized into four
groups: i) control, ii) P-PTX, iii) P-CYP and iv) combination of P-PTX and P-CYP.

Figure 9. In vivo representative bioluminescent images at day 7 and day 24.
Mice (n=5) from control (saline), P-PTX, P-CYP and P-PTX+P-CYP group were taken
bioluminescent images every alternative day from day 7 to day 24.

These polymer-drug conjugates were administered intravenously thrice a
week for two weeks at equivalent doses of 10 mg/kg PTX and 10 mg/kg CYP. All
the treatment groups had significantly lower tumor growth compared with the
control group. However, a significantly higher tumor growth inhibition was
observed in the group treated with the combination therapy compared with the
formulations containing either P-PTX or P-CYP (Figure 10A-B).
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Figure 10. In vivo efficacy of P-PTX and P-CYP after systemic administration in
PC-3 orthotopic prostate cancer bearing athymic nude mice. Mice (n=5) received
10 mg/kg P-PTX, 10 mg/kg P-CYP either alone or in combination at day 7 after tumor
implantation. A) Radiance intensity plot of all groups were measured from day 7 to
day 24. Data represented as the mean ± SEM, B) Representative tumors of each
group were excised after sacrificing the mice at the end of the experiment, C) Body
weight of each group.

The body weights of the mice did not drop after systemic administration of
saline or polymer-drug conjugates, with steady increase at similar rates in all
groups (Figure 10C). This indicates that P–PTX, P–CYP and their combination
are well tolerated. In addition, the chronic toxicities of these formulations were also
evaluated by histological analysis of the major organs (Figure 11). No obvious
histological changes were observed in the livers, spleens, kidneys and hearts from
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all the treatment groups.

Figure 11. Hematoxylin and Eosin (H&E) staining of major organs (liver, spleen,
kidney and heart). Organ samples from control (saline), P-PTX, P-CYP and P-PTX +
P-CYP treated groups were excised, fixed and stained for H&E.

Immunohistochemical analysis showed tumor sections from P-PTX, P-CYP
and combination of P-PTX with P-CYP treated group had significant necrotic area
with less number of live tumor cells, whereas control tumor remained viable.
Notably, the combination therapy showed more necrotic areas compared with
monotherapy. Furthermore, mice treated with the combination therapy showed
least Ki-67 staining compared with P-PTX, P-CYP and control treated groups
(Figure 12A). In TUNEL assay, control group did not have much TUNEL-positive
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green fluorescent cells while P-PTX or P-CYP treated group showed modest
increase in the number of apoptotic cells. The combination of P-PTX and P-CYP
showed significantly enhanced apoptosis supporting the tumor growth inhibition
potential of this combination therapy (Figure 12B).

Figure 12. Analysis of tumor samples for hematoxylin and eosin (H&E) and Ki67 (cell proliferation marker) staining and TUNEL assay. Control (Saline), P-PTX,
P-CYP and P-PTX + P-CYP treated tumor samples were excised, fixed and
immunostained for H&E and Ki-67 (A), and stained for TUNEL-positive nuclei (green)
and propidium iodide (red) positive nuclei (B).
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2.4 DISCUSSION
HRPC poses a medical challenge due to its insensitivity to the majority of
chemotherapeutic agents after long-term treatment. Emerging therapies directed
against different pathways include mTOR, MAPK/ERK, NFκB/IL-6, endothelin A
receptor, and

somatostatin

receptor

[56].

While

these

therapies

have

partially restored the sensitivity of prostate tumors to taxanes like PTX and DTX,
the benefit was only moderate or little compared to monotherapy.
Supplementation of Hh signaling inhibitor to chemotherapy has the potential
to eliminate the chemoresistance in advanced prostate cancer and to improve the
therapeutic efficacy of PTX by targeting both bulk tumor cells and CSCs, and
restoring the expression of dysregulated miRNA. Emerging evidence suggests that
numerous dysregulated miRNAs are implicated in the pathogenesis of prostate
cancer. Since expression profiles of miRNAs in tumors are tissue-specific [57],
miRNA could be not only an ideal class of biomarkers for cancer detection, but
also promising targets for cancer therapy. Therefore, CYP as an Hh signaling
inhibitor will augment PTX therapy by restoring the expression of tumor suppressor
miRNAs and thereby would improve the overall efficacy of chemotherapy.
For improved clinical translation of the combination therapy with reduced
toxicity and better safety, we conjugated PTX and CYP to a biodegradable
amphiphilic diblock copolymer mPEG-b-PCC with pendant carboxyl acid groups.
We have previously conjugated a water soluble drug gemcitabine as well as
dodecanol to mPEG-b-PCC. This polymer-drug conjugate self-assembled into
micelles and showed enhanced stability and antitumor effect of gemcitabine [58].
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In this study, PTX was conjugated to mPEG-b-PCC through an ester bond at its
2’-OH position which is more active than other two hydroxyl groups. For binding
CYP to mPEG-b-PCC we used a linker containing thiazolidine-2-thione to react
with secondary amine in CYP (Figure 1). Additionally, the attachment of DC
enhanced requisite hydrophobicity and assisted in the self-assembling of polymerdrug-conjugate micelles. These polymer-drug conjugates were characterized by
1H

NMR (Figure 2). Therefore, this conjugation strategy imparted high payload of

PTX (25.4±3.7%) and CYP (14.5±1.6%) and small micellar sizes of 70-76 nm.
Since the preparation of physical encapsulation of drugs into micelles is easier
compared to polymer-drug conjugation, we also physically encapsulated PTX and
CYP into mPEG-b-PCC-g-DC by film hydration. As expected, drug loading in these
physically drug encapsulated micelles was 8.21±0.01% for PTX and 5.36±0.07%
for CYP.
Physically encapsulated drugs into polymeric micelles are usually released
fast, with burst release due to the dynamic instability of micelles. This means
higher initial drug loading is needed because drugs should ideally be released at
the disease site to reduce their adverse effects. In contrast, chemical conjugation
of drugs to amphiphilic polymers via ester, amide, and disulfide bonds prevents
immediate drug release during the transport of polymer-drug conjugates and
provides long-term sustained release of drugs. Therefore, polymer-drug
conjugation prolongs drug circulation and therapeutic efficacy. To confirm the
different drug-release profiles between chemical conjugation and physical
encapsulation we also determined the release of PTX and CYP from physically
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drug encapsulated micelles. As expected, both PTX and CYP were released very
fast, with the burst release of these two drugs in the first 12 h and almost 60%
release at 24 hours (Figure 5), which is in good agreement with the literature
[59,60]. In contrast, PTX and CYP were released from conjugated micelles at a
slow but appreciable rate, which suggested that these polymer-drug conjugate
micelles could prolong the circulation of PTX and CYP. The percentage of PTX
and CYP released from significantly increased as pH was decreased from 7.4 to
5.3. However, even after six days, only about 25% of PTX and CYP were released
at pH 5.3, but only 10% of PTX and CYP were released at pH 7.4 (Figure 4A).
So far polymer-drug conjugates with linear backbone have undergone
clinical

evaluation,

such

as

polyethyleneglycol

(PEG),

poly[N-(2-

hydroxypropyl)methacrylamide] (PHPMA) copolymers, dextran and poly(glutamic
acid) (PGA) and they display numerous features and advantages among all nanosized carriers for cancer therapy [61-63]. Our polymer-drug conjugate micelles
offer distinct advantages in terms of a) PEG corona on the polymer imparts stealth
property; b) conjugation ensures in vivo stability and no premature drug release in
the circulation; c) small size of these micelles can take advantage of the EPR effect
to maximize drug delivery to prostate tumor.
We previously demonstrated that CYP could target CSCs derived from
PTX-resistant prostate cancer cell lines DU145-TXR and PC3-TXR and
combination therapy of PTX and CYP could reverse PTX chemoresistance and
eliminate CSC fraction in chemoresistant prostate cancer cells [64]. Therefore, in
this study we evaluated the inhibitory effect of P-PTX and P-CYP on DU145-TXR
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and PC3-TXR cells. We first determined cellular uptake of the conjugates. PTX
was replaced by a fluorescent taxol derivative flutax-1 which was conjugated to
mPEG-b-PCC along with dodecanol to obtain P-flutax-1. Green-fluorescent
positive PC3-TXR cells confirmed the successful cellular internalization of the
conjugates (Figure 6). In followed cytotoxicity assay P-PTX with 0.5 μM equivalent
PTX was not able to kill many cells due to the development of resistance to PTX.
However, the treatment with the combination of 0.5 μM PTX and 10 μM P-CYP for
72 hours killed almost half of the cells (Figure 7), which is in good agreement with
our previous observation [64]. This further suggests that this combination therapy
had potentials to treat chemoresistant prostate cancer.
Treatment of DU145-TXR and PC3-TXR cells with 10 µM P-CYP alone or
in combination with 0.5 µM P-PTX resulted in upregulation of tumor suppressor
miRNAs like miR-29b, miR-34a, miR-148a and miR-200c (Figure 8), leading to
increase in chemosensitivity to PTX. Emerging evidence demonstrates that miR200c, a member of miR-200 family, is one of the essential regulators of
chemoresistance as well as epithelial-mesenchymal transition (EMT). Expression
level of miR-200c is significantly downregulated in DTX-resistant prostate cancer
cells compared with non-resistant cells and restoration of miR-200c results in
apoptosis of DTX–resistant cells and reversal of EMT [65]. As tumor suppressor
miRNA, miR-34a not only has strong inhibitory effects of prostate cancer but also
can negatively affect prostate CSCs on the tumor-initiating ability and inhibit their
CSC properties such as sphere formation and clonogenic capacity [66]. miR-29b
can repress expression of Hh pathway and the inhibition of this signaling leads to
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the restoration of miR-29b expression [45,67,68]. miR-148a is reported to inhibit
the proliferation and metastasis of PTX-resistant prostate cancer and also
attenuate the resistance to PTX [69]. Based on these evidences and combining
our results, we confirmed that chemoresistance to PTX could be due to the altered
miRNA expression. Therefore, the combination of P-PTX and P-CYP could
alleviate chemoresistance by targeting miRNAs participated in chemoresistance.
In vivo efficacy of P-PTX and P-CYP conjugate micelles was determined in
orthotopic tumor model developed by PC3-luc-GFP cells in athymic nude mice.
Promising results were obtained in three treated groups wherein the combination
therapy of P-PTX and P-CYP resulted in a significant reduction in tumor growth
rate and tumor size compared with the control group (Figure 10). In addition, the
significantly low level of cellular proliferation and high level of apoptotic cells found
in combination group demonstrated combined P-PTX and P-CYP reduces tumor
growth synergistically (Figure 12). Furthermore, our formulation carrying P-PTX
and P-CYP conjugate micelles were well tolerated as the vital organs such as livers,
spleens, kidneys and hearts did not show any histological changes after treatments
(Figure 11). These results are in good agreement with the work of Kopecek and
associates who demonstrated that the combination of HPMA-CYP and HPMADTX conjugates significantly inhibited prostate tumor growth [70]. Unlike our
current studies these authors used subcutaneous tumor model, while we have
evaluated our formulations in orthotopic prostate tumor model.
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CHAPTER 3 POLYMERIC MICELLAR DELIVERY OF NOVEL
MICROTUBULE DESTABILIZER AND HEDGEHOG SIGNALING
INHIBITOR FOR SYNERGISTICALLY TREATING
CHEMORESISTANT PROSTATE CANCER

3.1 INTRODUCTION
Prostate cancer (PCa) is the most common non-cutaneous malignancy and
the second leading cause of cancer related mortality in American men. PCa at
stage I/II can be treated by surgery or radiation therapy but if the cancer has grown
outside the prostate or come back after surgery or radiation, androgen deprivation
therapy may be used to reduce androgen levels. Unfortunately, after a certain
period the aggressive portion of prostate cancer cells develops resistance to
hormone

treatment

and

become

androgen

independent.

Alternatively,

chemotherapy is given along with hormone therapy to enhance therapeutic
efficacy. Docetaxel (Taxotere®) is a clinically approved drug to treat castrationresistant prostate cancer including metastatic prostate cancers and it has been
proven to provide a modest survival benefit for patients with advanced prostate
cancers. However, a potential challenge of using docetaxel or paclitaxel as cancer
treatment in the long term is that their anticancer activities could be hindered by
intrinsic or acquired drug resistance due to mutation of β-tubulin, affected
androgen receptor signaling or overexpression of drug efflux pumps (ATP-binding
cassette) in cancer cells [71-74]. Therefore, there is an urgent need to identify
novel therapeutic agents for treating docetaxel-resistant patients.
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A number of agents targeting colchicine binding cite of tubulin have been
reported to effectively inhibit tumors that are resistant to taxanes and vinca
alkaloids, suggesting that this type of tubulin inhibitors can circumvent the
limitations associated with clinically available tubulin inhibitors [75,76]. Previously,
we have synthesized and evaluated a series of novel microtubule destabilizers [7781], which can target colchicine domain of tubulin and interfere with tubulin
polymerization. Although these new compounds have shown potent anticancer
activity, tumor heterogeneity and the complexity of cell signaling pathways in tumor
microenvironment make curing cancer through monotherapy a formidable
challenge. Combination chemotherapy using two or more anticancer agents that
work together synergistically by different mechanisms of action can increase the
chance of long-term remission and prevent potential drug resistance. Hedgehog
(Hh) signaling participates in the initiation and progression of various cancers, thus
its aberrant activation is considered as a hallmark of cancers. Importantly, Hh
signaling is needed for regeneration of prostate epithelium through crosstalk with
androgen signaling, suggesting that inhibition of Hh pathway has the possibility to
induce anti-proliferative and apoptotic effect on prostate cancer cells [38,39,82,83].
Furthermore, Hh signaling involves in the initiation and maintenance of cancer
stem cells (CSCs), a subset of cancer cells with self-renewal and tumorigenic
potentials, which have been demonstrated to play key roles in chemoresistance,
metastatic progression and epithelial-mesenchymal transition [40-42]. In our
previous studies [64,84], we also have proved the significant benefit using
combination of Hh signaling inhibitor cyclopamine and paclitaxel to combat taxane-
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resistant prostate cancer cells in vitro and vivo. Recently, our group developed a
series of analogs of GDC-0449, a FDA-approved Hh pathway inhibitor, and one of
the analogs, MDB5, exhibited stronger inhibition to Hh pathway and anticancer
effect in vitro and vivo than GDC-0449 [85]. Therefore, in the current study we
propose that the new combination therapy of a novel microtubule destabilizer and
a novel Hh inhibitor can work synergistically through different mechanisms to treat
taxane-resistant prostate (Figure 13), as the microtubule destabilizer can kill bulk
tumor cells and the Hh inhibitor can suppress Hh signaling and the proliferation of
CSCs resulting in alleviation of chemoresistance.

Figure 13. Structures of QW-296 and MDB5.

In further, considering the hydrophobicity of the two novel agents requiring
an appropriate drug delivery carrier, we synthesized a diblock copolymer
poly(ethylene

glycol)-block-poly(trimethylene

carbonate-co-2-methyl-2-
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benzoxycarbonyl-propylene carbonate) (abbreviated as mPEG-p(TMC-MBC)) via
ring-opening polymerization and prepared polymeric nanoparticles to physically
encapsulate two small molecules leading to enhanced water solubility, prolonged
circulation and reduced side effects.
To sum up, the anticancer effect and corresponding mechanisms of the
combination chemotherapy was thoroughly determined by using different prostate
cancer cells and orthotopic mouse model. It is the first time we introduced a new
therapeutic strategy to treat taxane-resistant prostate cancer, which would bring
potential promise to improve current regimens.
3.2 METHODS
3.2.1 Materials
Poly(ethylene glycol) methyl ether (mPEG, Mn=5000, PDI=1.03) was dried
by anzeotropical distillation form anhydrous toluene just before use. Trimethylene
carbonate (TMC) was obtained from Polysciences. Anhydrous chloroform,
dichloromethane (DCM), toluene, stannous 2-ethylhexanoate (Sn(Oct)2), and
diethyl ether were available commercially from Aldrich and used as received.
Deuterated chloroform (CDCl3) was purchased from Cambridge Isotope
Laboratories. Other chemicals were all of analytic grade and were used without
further purification.
3.2.2 Cell culture
Human prostate cancer cell lines with taxane resistance DU145-TXR and
PC3-TXR were kindly provided by Dr. Evan T. Keller from University of Michigan.
The cells were cultured in RPMI1640 medium supplemented with 10% FBS and
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1% penicillin/streptomycin in a humidified incubator containing 5% CO 2 at 37 °C
and their resistance to taxane were maintained by adding 200 nM paclitaxel to
growth media biweekly.
3.2.3 Cytotoxicity of QW-296 and MDB5
PC3-TXR and DU145-TXR cells were used to determine the cytotoxicity of
QW-296, MDB5 or their combination. After attached to the bottom of plate, cells
were incubated with different concentrations of QW-296, MDB5 or combination for
another 72 h. Cell viability was then determined by MTT assay and the absorbance
was measured at 560 nm with subtraction of absorbance at 630 nm. Each group
was performed in triplicate and the data reported as the mean ± SEM.
3.2.4 Combination effect and their Interaction analysis
Chou-Talalay method and CompuSyn software were used to determine
whether the combination had synergism, additivity, or antagonism [86]. PC3-TXR
cells were treated with different combinations at a constant molar ratio, and the
combination index (CI) was then determined by the software. CI values below 0.9,
between 0.9 and 1.1, or above 1.1 indicate synergism, additivity or antagonism,
respectively.
3.2.5 Cell cycle analysis by propidium iodide staining
PC3-TXR cells were cultured in a 24-well plate and treated with QW-296,
MDB5 or their combination for 48 h and 72 h. Cells were harvested, fixed in 70%
ice-cold ethanol for 1 h and washed by PBS. A cell pellet containing 1 × 106 cells
was then re-suspended in 0.5 mL of FxCycle™ PI/RNase staining solution and
incubated for 15 min at room temperature. Cell cycle was measured by a flow
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cytometer (BD FACSCalibur NJ). Results from 20,000 fluorescent events were
obtained for analysis.
3.2.6 Colony formation assay
PC3-TXR cells were seeded at 300 cells/well into 6-well plates and allowed
to grow for two days. Treatment of QW-296, MDB5 or combination was given to
different wells. After a 7 day-incubation, colonies in each well were fixed by 10%
formalin, stained with 0.5% crystal violet solution and visualized under a
microscope. Each group was performed in triplicate.
3.2.7 Western blotting
Protein was isolated from PC3-TXR cells after 72 h treatment of QW-296,
MDB5 or combination and protein concentration was determined by Micro BCA TM
Protein assay kit (Thermo Fisher Scientific, Waltham, MA). Equal amounts of
protein (50 µg) were separated in 4–15% Mini PROTEAN® TGXTM Precast Gel
followed by transferring to polyvinylidenefluoride (PVDF) membranes by iBlot® Gel
Transfer system (Thermo Fisher Scientific, Waltham, MA). After the membrane
was blocked by Odyssey® Blocking Buffer (TBS), the following primary antibodies
were used: Shh (sc-9024), β-actin (sc-47778) (Santa Cruz Biotechnology, Dallas,
TX.) Subsequently, the membrane was incubated with their corresponding IRDye®
800CW secondary antibodies and target proteins were detected by Odyssey® CLx
Imaging System (LI-COR Biosciences, Lincoln, NE).
3.2.8 Synthesis and characterization of mPEG-poly(TMC-MBC)
Monomer 5-Methyl-5-benzyloxycarbonyl-1,3-dioxane-2-one (MBC) and the
copolymer mPEG-poly(TMC-MBC) were synthesized as reported previously with
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minor modification [87]. In brief, mPEG (1 g, 0.0002 mol), TMC (307 mg, 0.003
mol) and MBC (750 mg, 0.003mol) were mixed in a dried round bottom flask under
vacuum, and then Sn(Oct)2 (10 mol% relative to mPEG) as a catalyst was added
to the mixture to initiate polymerization. The reaction mixture was heated to 120 °C
for 24 h under stirring. Afterward, the product was dissolved in chloroform and
precipitated in a large amount of diethyl ether and dried under vacuum. The
purified copolymer was characterized by 1H NMR and spectrum was recorded on
a Bruker (500MHz, T=25 °C) using deuterated chloroform (CDCl3) as solvent.
3.2.9 Preparation and characterization of polymeric micelles
Polymeric micelles were prepared using thin-film hydration method. Briefly,
a given amounts of mPEG-p(TMC-MBC) and the anticancer compound (10% w/w
relative to the copolymer) were dissolved in chloroform in a glass vial and a thin
film was formed after removing solvent under reduced pressure. The lipid film was
hydrated by PBS buffer and the micelle solution was formed under ultrasonic bath
at 37 °C. The formulation was then centrifuged at 3000 rpm for 5 min followed by
membrane filtration to remove any unformulated drug. The hydrodynamic
diameters and zeta potentials were measured by a Zetasizer Nano ZS90 (Malvern,
Worcestershire, UK) at a scattering angle of 90°. Particle size distribution was
reported as the mean ± SEM. of three independent samples. Critical micelle
concentration (CMC) was determined using pyrene as a hydrophobic fluorescent
probe as described previously [87].
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3.2.10 Drug loading and encapsulation efficiency
Briefly, MDB5 and QW-296 loaded micelles were dissolved in acetonitrile
for drug extraction and drug content was determined by HPLC/UV-Vis analysis
(Shimadzu, Kyoto Japan) on Phenomenex Aqua C18 column (5µm, 250 mm×4.6
mm) using acetonitrile and water (55:45, v/v) as mobile phase. Detection
wavelength of QW-296 and MDB5 were 222 nm and 261 nm, respectively. Payload
and encapsulation efficiency were calculated using the following equations:
𝑤
amount of extracted drug
Drug Loading ( %) =
× 100%
𝑤
total weight of formulation
Encapsulation Efficiency (%) =

amount of extracted drug
× 100%
initial weight of drug

3.2.11 Drug release from polymeric micelles
Drug-loaded micelles with a final concentration of 1 mg/mL were placed into
a dialysis membrane with a molecular weight cut-off of 3500 Da and dialyzed
against 50 mL buffer solution (0.1 M acetic acetate, pH 6.5 or 0.1 M PBS, pH 7.2)
with 0.5% Tween-80 in a thermo-controlled shaker with a stirring speed of 100 rpm.
1 mL samples were withdrawn at specified times for a period of five days and drug
concentration was analyzed by HPLC. All experiments were performed in triplicate
and the data reported as the mean of the three individual experiments.
3.2.12 In vivo study
All animal experiments were performed in accordance with the NIH animal
use guideline and protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at University of Nebraska Medical Center. Orthotopic prostate
tumors were established in 8-week-old male athymic nude mice by injecting 1.5 ×

46

106 PC3TXR-luc cells suspended in 50 μl PBS into dorsum of the prostate gland.
Animals were randomly divided into five groups after one week and different
treatments were administered intravenously every three days for five times. Group
1 was kept as the control and received normal saline, group 2 received 10 mg/kg
QW-296 in micelle solution, group 3 received 10 mg/kg MDB5 in micelle solution,
group 4 received 5 mg/kg QW-296 and 5 mg/kg MDB5 in cosolvent (12%
Cremophor® EL, 12% ethanol and 76% PBS), and group 5 received 5 mg/kg QW296 and 5 mg/kg MDB5 in micelle solution. Body weight of mice was recorded
twice a week. At the end of the animal study (i.e., day 24), mice were sacrificed
and tumors as well as vital organs (liver, spleen, kidney and heart) were excised.
Three representative tumors were collected per group and fixed with 10% buffered
formalin for 24h. The fixed samples were embedded in paraffin and thin sections
of 4 μm were obtained and immunostained for hematoxylin and eosin (H&E) and
cleaved Caspase 3. The side effects of each treatment were evaluated by H&E
staining of the major organs.
3.2.13 Statistical analysis
Data were represented as the mean± SEM. The statistical comparisons of
the experiments were performed by two-tailed Student's t-test. P ﹤ 0.05 was
considered statistically significant.
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3.3 RESULTS
3.3.1 Better anticancer activity of two novel compounds compared with
their counterparts
We firstly confirmed that PC3-TXR and DU145-TXR cells exhibited high
resistance to docetaxel (Figure 14). In the contrast, QW-296 exhibited strong cell
killing activity against two taxane-resistant cell lines with IC50 at 80 nM and 100 nM,
respectively, as shown in Figure 1B. In addition, PC3-TXR cells showed more
sensitivity to QW-296 than DU145-TXR cells.

Figure 14. Cytotoxicity assay of Docetaxel and QW-296 on PC3-TXR and
DU145-TXR for 72h.

We also compared the anticancer effects of MDB5 and GDC-0449 using
the two cell lines (Figure 15). The results confirmed that both MDB5 and GDC0449 suppressed the growth of PC3-TXR and DU145-TXR cells in a dosedependent manner, while MDB5 showed significantly enhanced activity with IC50
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at 40 µM than its parent drug, indicating the expected benefit of developing novel
analog of GDC-0449.

Figure 15. Cytotoxicity assay of MDB5 and GDC-0449. A) PC3-TXR and B) DU145TXR for 72h.

3.3.2 Synergism of QW-296 and MDB5 against taxane-resistant PCa cells
After testing cytotoxicity of individual drug, we confirmed the advantages of
combination therapy with different concentrations (Figure 16). The concentrations
of QW-296 and MDB5 applied in combination were lower than their IC 50 in
monotherapy, but the results proved combination at low concentrations worked
efficiently than individual treatment. Combination of QW-296 (25 nM) and MDB5
(7.5 µM) only killed 20% of PC3-TXR, but when their concentrations were both
doubled the combination killed 72% of cells. Two different combinations (Q 20
nM/M 20 µM, or Q 40 nM/M 10 µM) killed 40% of cells, but when the concentration
of single drug was doubled (Q 40 nM/M 20 µM) the combination killed 70% of cells.
All the above results suggested the two small molecules worked together not in an
additive manner and the anticancer effect of their combination could enhance
significantly at a certain combination ratio.
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The interactions between the two drugs were determined by Chou-Talalay
method and CompuSyn software, and we analyzed their combinations with
different concentration ratios. The Combination Index (CI) values below 0.9,
between 0.9 and 1.1, or above 1.1 indicate synergism, additivity or antagonism,
respectively. The Fa (i.e. fraction affected, degree of growth inhibition) and CI
values of different combinations were summarized in Figure 16 B-D and Table 1.
When the combinations inhibited 50% of cells (i.e. Fa=50%), their CI values were
in the range of additive effect, however, strong synergistic effect (the lower CI, the
stronger synergism) was observed in three combinations when Fa level ranging
from 75% to 95%. These results indicated that when concentration of each drug
was around half of its corresponding IC50 dose, their combination not only resulted
in high level of growth inhibition (75% or above) but also worked together in the
trend of synergism. Overall, this preliminary study explained the mechanism
behind the drug interaction between QW-296 and MDB5 and the benefit of
combination therapy was approved.
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Figure 16. Combination effect of QW-296 and MDB5 with various ratios against
PC3-TXR cells for 72h.

Table 1. Combination index of QW-296 and MDB5 with various ratios against PC3TXR

Combination index (CI)
Ratios of Q/M
Fa25

Fa50

Fa75

Fa90

1:200

1.81

0.92

0.54

0.34

1:300

2.39

0.94

0.43

0.32

1:400

2.49

0.87

0.35

0.16

Note: Q: QW-296; M: MDB5; Fa: fraction affected (%); CI > 1.1: antagonism; 0.9
< CI < 1.1: additivity; CI < 0.9: synergism
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3.3.3 Inhibition of colony formation
The inhibitory activity of QW-296, MDB5 and their combination on
tumorigenic potential in PC3-TXR cells was determined by colony formation assay.
As shown in Figure 17, it was not surprised that the number of colonies in
untreated group was the maximum compared with that of QW-296 alone, MDB5
alone, or the combination treated group. MDB5 at concentration of 15 μM exhibited
slight inhibition against colony formation, while QW-296 at concentration of 100
nM markedly suppressed the colony formation. However, combination of QW-296
at 50 nM and MDB5 at 15 μM almost resulted in no colony formation throughout 7
days. These data further confirmed the synergistic effect of QW-296 and MDB5 for
treating advanced prostate cancer.

Figure 17. Effect of QW-296 and MDB5 on colony formation of PC3-TXR cells.
300 PC3-TXR cells per well were seeded to 6-well culture plates. At 24h, drug
formulations were added and at 7 days, cell colonies were fixed, stained and counted.
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3.3.4 Effect of combination therapy on cell cycle, apoptosis and protein
expression
Cell cycle analysis and apoptosis was determined by PI-staining after 48 h
or 72 h of treatments to PC3-TXR cells (Figure 18). The data showed that QW296 (100 nM) caused immediate 35.84% G2/M phase arrested at 48 h, but the
percentage of arrested cells in G2 phase decreased to 25.76% with increase of
treatment time at 72 h. Meanwhile, QW-296 treatment could induce sub-G1 phase
arrest to 9.79% at 48 h and 11.43% at 72 h. In contrast to QW-296, MDB5 (15 µM)
resulted in 57.99% of cells arrested in G0/G1 phase at 48 h, along with 72.85% of
arrested cells in G0/G1 at 72 h, suggesting MDB5 affected on cell cycle through
different mechanism and it worked at a slow manner. The combination of QW-296
at 50 nM and MDB5 at 15 µM induced overall G2/M arrest at 48 h and 72 h. Unlike
single treatment changing cell arrest dramatically from 48 h to 72 h, combination
therapy caused cell arrested in G2 phase and these cells ended up in static status
throughout 72 h. Noticeably, after combination treatment the cell percentage of
PC3-TXR in sub-G1 phase was significantly enhanced to 19% compared with cell
percentage after monotherapy.
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A

B

Figure 18. Effect of QW-296 and MDB5 on cell cycle and apoptosis of PC3-TXR
cells. Cells were treated for 48 h or 72 h, stained with propidium iodide (PI), and
analyzed on a flow cytometer. (A) 48 h, (B) 72 h. Results were expressed as the mean
± SEM (n=3).

Meanwhile, as mentioned at the beginning of this paper, MDB5 was
designed as Hh signaling inhibitor and GDC-0449 analog, thus we determined the
effect of monotherapy or combination therapy on Hh signaling-related protein
expression. We found clear reduction of Shh proteins in MDB5 treated group and
combination treated group (Figure 19).
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Figure 19. Effect of QW-296 and MDB5 on Hedgehog signaling protein
expression of PC3-TXR cells.

3.3.5 Characterization of copolymer mPEG-p(TMC-MBC)
Monomer 2-Methyl-2-benzyloxycarbonyl-propylene carbonate (MBC) was
synthesized first as described previously. Then MBC and trimehtylene carbonate
(TMC) were copolymerized with methoxy PEG5000 using Sn(Oct)2 as a catalyst to
yield 1.82 g of copolymer mPEG-p(TMC-MBC) (88% yield). In 1H NMR spectrum
of mPEG-p(TMC-MBC), the following peaks were observed at δ 2.03 (CH2, br, 2H)
corresponding to TMC, δ 1.2 (CH3, s, 3H) and δ 7.3 (phenyl, m, 5H) corresponding
to MBC, δ 4.2-4.3 (CH2, t, 4H) corresponding to both TMC and MBC, and δ 3.63
(CH2, s, 2H) corresponding to PEG. The Mn of mPEG-p(TMC15-MBC15) determined
by 1H NMR was 10280 g/mol with 15 units of each block, respectively. (Figure 20).
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Figure 20. Synthetic route of copolymer mPEG-p(TMC-BC) (A) and its 1H NMR
spectra (B).
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3.3.6 Characterization, quantification and release profile of drug-loaded
mPEG-p(TMC-MBC) micelles
The amphiphilic nature of mPEG-p(TMC-MBC) drives self-assembly into
micelles in aqueous buffer. Surface morphology and mean particle size of micelles
were checked by transmission electron microscopy (TEM, Tecnai G 2 Spirit) and
dynamic light scattering (DLS, Zetasizer Nano ZS90). Unloaded, QW-296-loaded
and MDB5-loaded polymeric micelles had similar size distributions, which were 81
nm. The TEM image also showed that the micelles had a narrow size distribution
below 60 nm (Figure 21C) and confirmed that mPEG-p(TMC-MBC) formed
spherical micelles in PBS with distinct boundaries as anticipated. CMC value of
mPEG-p(TMC-MBC) was 6.65×10-4 g/L (Figure 21D), further indicating that the
micelles were quite stable in PBS. Meanwhile, high drug payload of these
polymeric micelles was determined by HPLC: 8.13±0.75% (w/w) for QW-296 and
9.12±0.69% (w/w) for MDB5, respectively (Table 2).

Table 2. Parameters of mPEG-p(TMC-BC) micelles

zeta
Mean

Drug loading Drug loading
potential

PDI

CMC (g/L)

size (nm)

of QW-296

of MDB5

8.13±0.75%

9.12±0.69%

(mV)
81.51

-1.45

0.143

6.65×10-4
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Figure 21. Characterization of polymeric micelles. (A) Hydrodynamic diameter, (B)
zeta potential, (C) TEM morphology, (D) critical micelle concentration.

To improve the bioavailability of QW-296 and MDB5 for cancer treatment,
controlled and sustained drug release is very important. Therefore, the release
profile of QW-296 and MDB5 from mPEG-p(TMC-MBC) micelles at different pH
was carried out by a dialysis method in PBS buffer (pH 7.4) and acetate buffer (pH
6.5). As shown in Figure 22, 40% of QW-296 or 25% of MDB5 was rapidly
released from the micelles within the initial 12 h. Then the release of QW-296 or
MDB5 increased up to 75% or 65% at 48 h followed by slower sustained profile
until the end of the 96 h. Furthermore, at pH 6.5, the liberation of QW-296 or MDB5
from polymeric micelles was accelerated as expected due to the instability of
micelles occurred in an acidic or basic environment. These data suggested that
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the drug-loaded micelles could release these drugs at expected speed under
physiologically simulating conditions.

Figure 22. In vitro release of QW-296 and MDB5 from drug encapsulated
micelles at pH 7.4 and 6.5. (A) QW-296, (B) MDB5. Drug concentrations from each
time point were measured by HPLC and drug release profiles were represented as
the mean± SEM.

3.3.7 In vivo antitumor efficacy in Orthotopic Prostate Cancer Mouse Model
We successfully established orthotopic prostate tumor in 8-week-old male
athymic nude mice by injecting 1.5x106 PC3TXR-luc cells into dorsal prostate lobe
(Figure 23). The mice whose bioluminescent radiance reached 10 8 were
randomized into five groups: 1) control, 2) QW-296 micelles (10 mg/kg), 3) MDB5
micelles (10 mg/kg), 4) combination of QW-296 and MDB5 in cosolvent (5 mg/kg
+ 5 mg/kg), 5) combination of QW-296 and MDB5 in micelles (5 mg/kg + 5 mg/kg).
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Figure 23. In vivo imaging of athymic nude mice bearing PC3-TXR orthotopic
prostate cancer. Representative bioluminescence images were took at day 7 and
day 24 (n = 6).

All the treated groups showed inhibition of tumor growth compared with
control group, however, the maximum tumor inhibition was observed in the group
treated with combination in micelles. Notably, combination of QW-296 and MDB5
in micelles exhibited stronger antitumor activity in comparison with combination
with same doses in cosolvent (Figure 24).
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Figure 24. In vivo efficacy of QW-296 and MDB5 after systemic administration in
PC3-TXR orthotopic prostate cancer bearing athymic nude mice. Representative
tumors of each group were excised after sacrificing the mice at the end of the
experiment.

Next, we performed immunohistochemical analysis to further elucidate the
superior anticancer efficacy of combination micelles. Hematoxylin and eosin (H&E)
stain of tumor sections indicated that tumor samples from four treated groups had
more necrotic area compared with tumor samples from control group, and tumors
from combination micelles group showed maximum necrosis. Furthermore,

61

cleaved caspase 3 stain indicated the induction of significant apoptosis by
combination micelles of QW-296 and MDB5 compared to other treatments (Figure
25). Meanwhile, the chronic toxicities of these treatments were also examined by
histological analysis of major organs. No distinct histological changes were
observed in the liver, spleen, kidney and heart from all treated groups, suggesting
that mice tolerated all treatments well (Figure 26).

Figure 25. Analysis of tumor samples by hematoxylin and eosin (H&E) and
Caspase 3 stain. Tumor samples from control and treated groups were excised, fixed
and immunostained for (A) H&E and (B) Caspase 3.
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Figure 26. Analysis of major organs by H&E stain. Organ samples from five groups
were excised, fixed and stained for H&E. No obvious histological changes were
observed in the livers, spleens, kidneys and hearts from all the treated groups.

3.4 DISCUSSION
Drug resistance is still one of the major impediments for the success of
chemotherapy and several factors account for the occurrence of resistance,
including ATP-binding cassette transporter family (P-gp, ABCC1, ABCG2, etc.)
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[88], alteration in drug targets, as well as intrinsic chemoresistance (cancer stem
cells, CSCs) [89]. With the advances in cancer research, there are numerous
approaches to overcome drug resistance. Combination chemotherapy is
considered as one of the preferred choice in both preclinical research and clinical
practice. Due to heterogeneity and molecular complexity of cancers, combination
therapy referring to administration of two or more anticancer agents with different
mechanisms of action can modulate various signaling pathways and maximize
therapeutic effects. In addition, it is worth mentioning that if the combinatory drug
effect is greater than the sum of their individual effects, as known as drug
synergism, there will be a higher chance in success of combination strategy. In this
regard, our study proposed a synergistic combination chemotherapy using two
novel anticancer agents to overcome taxane-resistance and treat advanced
prostate cancer.
To replace taxane treatment, we first designed and synthesized a new
microtubule destabilizer, QW-296, whose function on microtubule mass, different
from the stabilizers such as taxanes, was to suppress tubulin polymerization. On
the other hand, a novel Hh pathway inhibitor MDB5 was selected to ally with QW296 to treat advanced prostate cancer due to the emerging clinical reports that
over-expressed Hh pathway promotes prostate tumor formation from epithelial
cells, renders the epithelial-to-mesenchymal transition, and has cross-talk with
androgen pathway. In our previous study, we also demonstrated that the
combination of Hh inhibitor cyclopamine and paclitaxel effectively worked together
to suppress the growth of taxane-resistant prostate cancer in vitro and vivo by
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playing different roles on cancer cells, suggesting a promising combination
strategy. Thus, in the current study, we upgraded Cyclopamine to a newly
designed Hh signaling inhibitor MDB5, having stronger inhibition activity against
Hh signaling but less unfavorable toxicity compared with its parent drug GDC-0449.
First, the inhibitory effect of QW-296 and MDB5 on prostate cancer cells was
confirmed by cell viability and colony formation assay, clearly indicating the benefit
of this combination, and then their synergism was proved by Chou–Talalay method,
which strengthened our hypothesis preliminarily. In the following cell cycle analysis,
QW-296 and MDB5 made distinct impacts on cell cycle as QW-296 treatment
caused G0/G1 phase arrest while MDB5 treatment lead to G2/M phase arrest,
which demonstrated two anticancer agents worked at complementary mechanism
of action against PC3-TXR cells, and this result was in the agreement with previous
reports. In further we analyzed the expression change of relevant protein to
highlight the combination advantage at molecular level. We observed Shh, a key
downstream component of Hh signaling pathway, were highly downregulated after
MDB5 monotherapy or combination of QW-296 and MDB5, indicating the
treatment did have effect on Hh pathway. All these results reinforced our
preliminary findings and provided us with a reasonable explanation on benefits of
the combination therapy.
Although QW-296 and MDB5 demonstrated excellent synergy of anticancer
activity against chemoresistant prostate cancer, their clinical translation will be
limited due to their intrinsic poor aqueous solubility as many other anticancer
agents. Therefore, to solve this problem, nanoparticle-based therapeutic systems
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have emerged as a promising platform for delivering hydrophobic drugs over
several decades. In this study, we developed an amphiphilic copolymer mPEGp(TMC-MBC) to encapsulate two hydrophobic small molecules, thereby forming
polymeric micelles in aqueous solution with nano-ranged particle size that are
suitable for systemic therapy in animal study. PEG5000 was used as hydrophilic
backbone and this long length enabled us to synthesize the copolymer with
molecular weight in the range of 10,000-11,000 Da. Its stealth-like property helped
resulting micelles prolong circulation time and accumulate the amount of drug at
target tumor tissue. On the other hand, two carbonate blocks TMC and MBC
provided desired hydrophobicity to wrap lipophilic molecules in the core and
balance hydrophilic composition as well. Our results also confirmed that polymeric
micelles mPEG-p(TMC-MBC) enabled appropriate drug loading for both drugs and
sustained drug release in acidic or neutral condition, which laid a foundation for
the success of combination therapy applied in animals or future clinical translation.
To better investigate the combination efficacy, we used half dose of QW296 and MDB5 in combination treatment as compared with monotherapy. All the
four treated groups exhibited excellent tumor inhibitory results. However,
combination therapy in micelles showed significantly enhanced reduction in tumor
size compared with the combination in co-solvent as well as QW-296 or MDB5
monotherapy. Apart from tumor growth suppression, H&E stain of vital organs
demonstrated the micelles carrying QW-296 and MDB5 were well tolerated, as
other healthy organs did not show obvious histological changes after treatments.
These results strongly supported our hypothesis that QW-296 and MDB5 could
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synergistically treat chemoresistant prostate cancer in vivo and copolymer mPEGp(TMC-MBC) could serve as a more effective delivery vehicle to boost anticancer
activity of two drugs than co-solvent.
3.5 CONCLUSION
In the present study, we successfully synthesized and screened a novel
microtubule destabilizer QW-296 and a Hh pathway inhibitor MDB5 and
demonstrated their anticancer activities in combination or individually. The
copolymer mPEG-p(TMC-MBC) was successfully synthesized and formed
polymeric micelles to encapsulate QW-296 and MDB5 with desirable drug payload
and small particle sizes. The overall findings indicated that the combination of QW296 and MDB5 exhibited the synergistic therapeutic effect against chemoresistant
prostate cancer via different mechanism, and with the help of mPEG-p(TMC-MBC)
the combination could effectively inhibit the growth of chemoresistant prostate
cancer in vivo. Given these encouraging results, our micelles of QW-296 and
MDB5 provide a promising therapeutic strategy for chemoresistant prostate cancer
therapy.
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CHAPTER 4 POLYMER CONJUGATE OF A MICROTUBULE
DESTABILIZER INHIBITS LUNG METASTATIC MELANOMA2

4.1 INTRODUCTION
Over the past several decades, the development of nanomedicines has
been driven by the increasing demands of delivering therapeutic agents to disease
sites efficiently. A large amount of pioneering research has highlighted applications
of micelles, nanoparticles, liposomes, polymersomes, nanogels and dendrimers
as nanocarriers of low molecular-weight drugs, oligonucleotides and genes.
Polymer-drug conjugates debuted in 1955 [90], and in the mid-1970s Ringsdorf
proposed the idea of conjugating therapeutic agents to water soluble polymers [91].
Since then, the field of polymer-drug conjugates started a new era of drug delivery
and has been growing fast. Advantages of conjugates over their corresponding
parent drugs include: 1) increased aqueous solubility of hydrophobic drugs; 2)
prolonged blood circulation time; 3) enhanced bioavailability; 4) increased
protection of drugs from degradation; 5) increased tumor accumulation either due
to enhanced permeability and retention (EPR) effect or tunable targeting moieties.
Unlike physically drug encapsulation into nanoparticles and micelles, covalent
drug conjugation to polymers achieves enhanced drug payload and prevents
premature drug release, thereby decreasing undesired toxicities compared to
physically drug-encapsulated liposomes, nanoparticles and micelles. The polymer-

2

R. Yang, G. Mondal, R.A. Ness, K. Arnst, V. Mundra, D.D. Miller, W. Li, R.I. Mahato, Polymer
conjugate of a microtubule destabilizer inhibits lung metastatic melanoma, J. Control. Release.
249 (2017) 32-41.
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drug conjugate market is currently becoming well-established with several
commercialized products available for a wide range of disease states, such as
Adynovate by Baxalta, Movantik™ by AstraZeneca, Oncospar® by Enzon
Pharmaceuticals, Plegridy® by Biogen, etc.
Malignant melanoma is the most invasive form of skin cancer with high
metastatic propensity, typically metastasizing to the lymph nodes, lungs, liver,
brain and heart at late stage of melanoma. The median overall survival time of
patients suffering from metastatic melanoma is less than one year, and only about
10% of these patients survive more than 5 years after diagnosis [92]. Unfortunately,
the survival of patients with advanced metastatic melanoma has not been
significantly improved by current Food and Drug Administration (FDA)-approved
systemic

chemotherapies

[93].

Dacarbazine

(DTIC),

a

widely

used

chemotherapeutic agent for treatment of metastatic melanoma, shows transient
efficacy in most patients, however, only 1–2% of patients achieve a durable longterm response to this therapy [94]. The combination of paclitaxel and carboplatin
is used as second-line therapy for patients who suffer from disease progression
while receiving DTIC treatment. Clinical benefit of this combination therapy was
noted in more than 40% of all patients in the original study [95,96]. Nevertheless,
a potential problem when using paclitaxel or other microtubule inhibitors for cancer
treatment in the long term is that their anticancer effects could be undermined by
intrinsic or acquired drug resistance due to overexpression of drug efflux pumps
(P-glycoprotein, MRP and BCRP) in cancer cells [71-73]. To address this problem,
we have synthesized a series of novel microtubule destabilizers, substituted
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methoxybenzoyl-ary-thiazole (SMART) compounds, with nanomolar anticancer
activity against melanoma, breast cancer, ovarian cancer, colon cancer and
prostate cancer [97]. In addition, their ability to circumvent P-gp mediated drug
resistance was confirmed by using prostate cancer cells with P-gp overexpression
[98]. However, the clinical translation of SMART compounds is limited due to their
poor aqueous solubility as many other anticancer agents. Moreover, these small
molecular weight drugs are rapidly eliminated from the circulation, requiring
frequent dosing, leading to increased risk of side effects. To address this issue, we
formulated SMART-100 in micelles using poly (ethylene)-b-poly(D,L-lactide)
(PEG-PLA) in a previous study, but the utility of physical encapsulation is limited
by low drug payload. Therefore, in the current study we synthesized a new SMART
analogue, SMART-OH and conjugated this compound to the carboxyl pendant
groups of poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene
carbonate) (mPEG-b-PCC). The polymeric conjugate

consists of

three

components including biocompatible PEG blocks, a biodegradable polycarbonate
backbone and lipid chains of dodecanol (DC). The anticancer effect of SMARTOH and its polymer-drug conjugate mPEG-b-PCC-g-SMART-g-DC (abbreviated
as P-SMART) on melanoma cells was determined. Furthermore, a mouse model
of metastatic melanoma to the lungs was established to study in vivo efficacy of PSMART as well as SMART-OH.
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4.2 METHODS
4.2.1 Materials
4-Cyanophenol, L-cysteine, N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1yl)uranium
(TBDMSCl),

hexafluorophosphate
n-butyllithium,

(HBTU),

tert-butyldimethylsilyl

tetra-n-butylammonium

fluoride,

chloride
2,

2-

bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, Mn
=5000), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N-(3-dimethylaminopropyl)N′-ethylcarbodiimide hydrochloride (EDC) 98%, 1-hydroxybenzotriazole (HOBT),
Benzyl bromide, Dodecanol (DC), diisopropylethylamine (DIPEA) and cremophor®
EL were purchased from Sigma Aldrich (St. Louis, MO). FxCycle™ PI/RNase
staining solution was purchased from ThermoFisher Scientific (Waltham, MA).
Bovine brain tubulin was purchased from Cytoskeleton (Denver, CO).
4.2.2 Synthesis and characterization of SMART-OH
2-(4-Hydroxyphenyl)-4,5-dihydrothiazol-4-yl-3,4,5trimethoxyphenyl)methanone (abbreviated as SMART-OH) was synthesized as
shown in Figure 27 (compound 5). Briefly, 4-cyanophenol (1 equiv.) was mixed
with L-cysteine (1 equiv) in a 1:1 solution of MeOH/pH 6.4 PBS. The reaction
mixture was heated to 40 °C and stirred for 3 days. The mixture was then filtered
to remove the precipitate and MeOH was removed using a rotary evaporator. The
remaining solution was then acidified to pH 4 using 1M HCl and CH2Cl2 was added
to the solution. The resulting precipitate was filtered to yield a white solid,
compound 1. This solid was dried overnight in a vacuum desiccator and then used
directly for the next step.
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Compound 1 (1 equiv.) was dissolved in anhydrous CH2Cl2. HBTU (1.1
equiv) was then added and stirred for 15 minutes. This was followed by addition of
DIPEA (2.2 equiv) which was stirred for 2-3 minutes. Finally, HNCH3OCH3 HCl salt
(1.1 equiv.) was added and the reaction was stirred at room temperature for 12-18
hours. The reaction mixture was washed once with ddH2O and twice with saturated
NaCl solution. The organic layer was then dried over MgSO 4. The solvent was
removed by a rotary evaporator to yield crude yellow oil. This was then purified by
flash chromatography to obtain compound 2.
A solution of compound 2 (1 equiv.) in anhydrous tetrahydrofuran (THF)
was kept under argon and cooled to 0 °C. Imidazole (2.5 equiv.) and TBDMSCl (2
equiv) were then added to the solution and the mixture was stirred for 12-18 hours.
The solvent was removed by a rotary evaporator and the resulting solid was
dissolved in CH2Cl2 and washed once with ddH2O and once with saturated NH4Cl
solution. The organic layer was dried over NaSO 4 followed by purification using
flash chromatography to yield compound 3.
Compound 3 (1 equiv) was dissolved in freshly distilled THF at room
temperature while 3,4,5-methoxylphenyl (1.2 equiv) was dissolved in freshly
distilled THF in a separate flasks and cooled to -78 °C under argon. n-Butyllithium
(1.5 equiv) was then added to the cooled mixture and stirred at -78 °C for 30
minutes. The solution containing compound 3 was then added to the mixture and
stirred for 2 hours while returning to room temperature. The reaction was quenched
with saturated NH4Cl solution, extracted three times with ethyl acetate, dried over
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NaSO4, and purified by flash chromatography to yield a bright yellow solid,
compound 4.
Compound 4 (1 equiv) was then dissolved in THF and cooled to 0 °C. Tetran-butyl ammonium fluoride (2 equiv) was then added and the mixture was stirred
for 10 minutes. The reaction was quenched with saturated NH 4Cl solution,
extracted three times with ethyl acetate, dried over NaSO4, and purified using flash
chromatography to yield the final pure product (compound 5, Figure 27).
4.2.3 Docking
Docking studies were carried out using the crystal structures of the α,βtubulin dimer in complex with DAMA-colchicine (Protein Data Bank code 1SA0).
Schrodinger Molecular Modeling Suite 2016 (Schrodinger Inc., Portland, OR)
running on Microsoft Windows 7 platform was used to perform these studies,
similar to what we described in previous reports [99-101]. Briefly, the protein-ligand
complex was prepared using the Protein Preparation module, and SMART-OH
was docked into the colchicine binding site in the structure of 1SA0 using Glide
module. Data analyses were performed using the Maestro interface of the software.
4.2.4 Tubulin polymerization assay
Bovine brain tubulin (3.33 mg/m) was exposed to 10 µM of SMART-OH,
colchicine or vehicle control (5% DMSO), respectively, and incubated in 100 µl of
general tubulin buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA and 1 mM
GTP; pH 6.9). Absorbance at 340 nm was monitored at 37°C every minute for 15
min by the SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT).
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4.2.5 Synthesis and characterization of mPEG-b-PCC-g-SMART-g-DC (PSMART)
2-Methyl-2-benzyloxycarbonyl-propylene carbonate (MBC), poly(ethylene
glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) (mPEG114b-PBC28) and poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene
carbonate) (mPEG114-b-PCC28) were synthesized as described previously [54].
SMART-OH and DC were conjugated to the carboxyl groups of mPEG114-b-PCC28
copolymer using carbodiimide coupling. MPEG-b-PCC (180 mg, 0.019 mmol) was
dissolved in anhydrous CH2Cl2 followed by addition of EDC (215 mg, 1.12 mmol),
HOBT (101 mg, 0.75 mmol) and the solution was stirred at room temperature. After
two hours, N,N-diisopropylethylamine (DIPEA, 98 μl, 0.56 mmol) and SMART-OH
(84 mg, 0.23 mmol) were added and the reaction continued for two days. Then,
DC (70 mg, 0.37 mmol) was added and the reaction was allowed to proceed for
one additional day (Figure 29A). Crude product was purified by precipitation in
large excess of diethyl ether and then by dialysis against MeOH using a
regenerated cellulose membrane with 3.5 K MWCO.
1H

NMR spectrum was recorded on a Bruker (500 MHz, T = 25 °C) using

DMSO-d6 as solvent for P-SMART in a chemical shift range of 0-12 ppm.
Dynamic light scattering (DLS) was used for measuring the particle size
distribution of P-SMART. Briefly, 10 mg of P-SMART was dissolved in CH2Cl2 and
the solvent was evaporated under reduced pressure. The resulting film was
hydrated with 1 ml PBS (pH 7.4) followed by sonication and filtration through 0.22
μm filter. Mean particle size was measured by using a Zetasizer Nano ZS90
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(Malvern, Worcestershire, UK) at a scattering angle of 173°. A total of 12
measurements were taken per sample with a time span of 10 s. Particle size
distribution was reported as the mean ± SEM. of three independent samples.
4.2.6 Quantification of SMART payload in P-SMART
To quantify the conjugated drug, alkaline hydrolysis method was used. 1
mg/ml P-SMART was mixed with 1 ml NaOH (1 N) at 37 °C overnight. Samples
were then neutralized to pH 7.4 followed by HPLC-PDA analysis. Chromatography
was performed on Phenomenex® column (250×4.6 mm; 5 μm) using acetonitrile
and water (60:40, v/v) as mobile phase and wavelength of 300 nm. The stability of
SMART-OH was also tested under the same alkaline hydrolysis conditions at 37 °C
overnight to determine if there was any degradation of SMART-OH. The data was
reported as the mean ± SEM of three individual experiments. Payload was
calculated using equation 1.
𝑤
amount of hydrolysed drug
Payload ( %) =
× 100%
𝑤
total weight of polymer drug conjugate
4.2.7 In vitro drug release
Drug release from the P-SMART conjugate was determined at pH 6.5 and
7.4. Briefly, 1 mg of P-SMART was suspended in 1 ml buffer solution (0.1 M acetic
acetate, pH 6.5 or 0.1 M PBS, pH 7.4) and diluted with MeOH in a volume ratio of
MeOH: aqueous solution (1:4, v/v). All samples were incubated at 37 °C, shaken
at 100 rpm for 0, 3, 6, 9, 12, 24, 48, 72, 96, 120 h, and neutralized to pH 7.4 prior
to HPLC analysis as described in previous section. All experiments were
performed in triplicate and the data reported as the mean ± SEM of three individual
experiments.
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4.2.8 Cell culture
Human melanoma cell line A375, mouse melanoma cell lines B16-F10 and
B16-F10-luc were cultured in DMEM medium supplemented with 10% FBS and 1%
penicillin/streptomycin. All cell lines were grown and maintained in a humidified
incubator containing 5% CO2 at 37 °C.
4.2.9 Cytotoxicity assay
A375 and B16-F10 cells were used to determine the cytotoxicity of PSMART and parent drug. After attached to the bottom of plate, cells were
incubated with different concentrations of SMART-OH or P-SMART for another 72
h. Cell viability was determined by MTT assay and the absorbance was measured
at 560 nm with subtraction of absorbance at 630 nm. Each group was performed
in triplicate and the data reported as the mean ± SEM.
4.2.10 Colony formation assay
A375 or B16-F10 cells were seeded at 250 cells/well into 6-well plates and
allowed to attach for 24 h. Cells were then treated with SMART-OH or P-SMART
at different concentrations. After a 7 day-incubation, colonies in each well were
fixed by 10% formalin, stained with 0.5% crystal violet solution and visualized
under a microscope. Each group was performed in triplicate.
4.2.11 Transwell invasion assay
Cell invasion experiments were carried out using 24-well plates and cell
culture inserts with 8 μm pore size (Corning®). The upper sides of the inserts were
coated with 40 μL Matrigel® diluted 1:4 (v/v) with serum-free DMEM, were placed
in a 24-well plate, and were incubated for 2 h at 37 °C. B16-F10 cells were
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suspended in serum-free DMEM and placed in the upper chamber of the Transwell
insert (1×105 cells/ml) with treatment of SMART-OH or P-SMART at a dose of 0.5
μM. Cell suspension without treatment was used as a control. DMEM containing
10% FBS was added to the corresponding lower chamber. After 24 h, the noninvaded cells in the upper chamber were removed by a cotton swab and the
invaded cells were fixed with 10% formaldehyde in PBS and stained with 0.5%
crystal violet solution. Each group was conducted in triplicate wells and three 40X
imaging areas were randomly selected for each well.
4.2.12 Cell cycle analysis by propidium iodide staining
A375 and B16-F10 cells were used for cell cycle analysis. Cells were
cultured in a 24-well plate to 80% confluence and treated with P-SMART for 48 h.
Cells were harvested, fixed in 70% ice-cold ethanol for 1 h and washed by PBS. A
cell pellet containing 1x106 cells was then re-suspended in 0.5 mL of FxCycle™
PI/RNase staining solution and incubated for 15 min at room temperature. Cell
cycle was measured by a flow cytometer (BD FACSCalibur NJ). Results from
20,000 fluorescent events were obtained for analysis.
4.2.13 In vivo study
All animal experiments were performed in accordance with the NIH animal
use guidelines and protocol approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Nebraska Medical Center (UNMC),
Omaha, NE. A mouse model of metastatic melanoma to the lung was established
5

in 8 week-old female C57BL/6 albino mice by injecting 2 × 10 B16-F10-luc cells
suspended in 100 μL PBS into their tail vein. Mice were randomly divided into three
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groups of five animals per group when the radiance of tumor had reached 10 5.
SMART-OH and P-SMART were administered intravenously to mice once every
three days for a total of five times. Group 1 was kept as the control and received
normal saline, group 2 received 20 mg/kg SMART-OH in 35 % of cosolvent (50%
propylene glycol, 30% Cremophor® EL, and 20% ethanol) and 65 % of dextrose
solution, and group 3 received 20 mg/kg P-SMART (equivalent to free SMARTOH). Bioluminescent radiance of tumor was measured every other day using IVIS ®
Spectrum imaging system (PerkinElmer Inc., MA). At the end of the animal study
(i.e., day 24), mice were sacrificed and tumors as well as vital organs (liver, spleen,
kidney and heart) were excised.
In a separate survival study, mice were randomly divided into three groups
of seven mice for different treatments as described above. Survival observation
of mice ceased when death occurred due to uncontrolled tumor growth or the
toxicity of treatments. Three representative tumor tissues were collected per group
and fixed with 10% buffered formalin for 24h. The fixed samples were embedded
in paraffin and thin sections of 4 μm were obtained and immunostained for
hematoxylin and eosin (H&E) and cleaved Caspase 3.
4.2.14 Statistical analysis
Data were represented as the mean ± SEM. The statistical comparisons of
the experiments were performed by two-tailed Student’s t test. P <0.05 was
considered statistically significant.
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4.3 RESULTS
4.3.1 Characterization and molecular docking of SMART-OH in tubulin
The structures for all synthesized compounds were characterized and
confirmed by NMR and high resolution mass spectrometry. The proton NMR for
final compound 5 (SMART-OH) was shown in Figure 27.

Figure 27. Synthesis and characterization of SMART-OH.

Docking studies (Figure 28A) indicated excellent binding and interactions
between SMART-OH and the tubulin dimer. SMART-OH and the native ligand in
the crystal structure of 1SA0 showed good overlap when they bind to the colchicine
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binding site in tubulin (Figure 28A, enlarged portion). Three hydrogen bonds were
formed between SMART-OH and the tubulin dimer, namely oxygen in the 4methoxy moiety to Cys241; the carbonyl to Asp-251; and the phenol to Val315.
These three hydrogen bonds anchor SMART-OH tightly in this colchicine binding
pocket, predicting effective disruption of tubulin polymerization.

Figure 28. Inhibition of SMART-OH on tubulin. A) Molecular docking. Docking
image showed that SMART-OH bind to the colchicine binding site in tubulin. B) Tubulin
polymerization assay. Tubulin (3.33 mg/ml) was exposed to 10 µM of SMART-OH,
colchicine or vehicle control (5% DMSO), respectively, and incubated in general
tubulin buffer. Absorbance at 340 nm was monitored at 37°C every minute for 15 min.
Both SMART-OH and colchicine effectively inhibited polymerization, while robust
polymerization was observed in the control group.

4.3.2 Inhibition of tubulin polymerization
To evaluate the ability of SMART-OH to directly interact with tubulin and
confirm its mode of action, we performed a microtubule polymerization assay in
vitro. A vehicle and colchicine (10μM), a well-known microtubule destabilizing
agent, were used as controls and assayed under the same conditions. Robust
polymerization is observed in the control group, while both SMART-OH and
colchicine effectively inhibit polymerization (Figure 28B). This result is consistent
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with the proposed mechanism of action of SMART-OH compound as a potent
tubulin polymerization inhibitor.
4.3.3 Characterization and quantification of P-SMART
P-SMART was synthesized by direct carbodiimide coupling of SMART-OH
onto the pendant carboxylic acid groups of the hydrophobic block of mPEG-b-PCC
copolymer (Figure 29A). In

1H

NMR spectrum of mPEG-b-PCC, protons

corresponding to −CH2−CH2−O− of PEG at δ3.4−3.6, −CH2− units of PCC at
δ4.2−4.4 and −COOH at δ12−14 were observed and reported earlier by our group.
After conjugation of SMART-OH to mPEG-b-PCC, protons corresponding to
SMART were all observed in 1H NMR spectrum.1H NMR (500 MHz, DMSO-d6)
spectrum of mPEG-b-PCC-g-SMART-g-DC showed peaks corresponding to PEG:
(−CH2−CH2−O-) at δ3.5, PCC: (−CO-O-CH2-C-) at δ4.2 (m, 4H), (−CO-O-CH2-CCH3) at δ1.1-1.3 (t, 3H), Dodecanol: CH3-(CH2)9- at δ0.9 (t, 3H), CH3-(CH2)9- at
δ1.0-1.3 (bs, 18H), CH3-(CH2)9-CH2 at δ1.6 (m, 2H), CH3-(CH2)9-CH2-CH2- at δ4.3
(m, 2H), SMART-OH: benzene -CH- at δ8.1 (dt, 2H), δ7.6 (dt, 2H), δ7.2 (t, 2H),
thiazole -CH- at δ8.7 (s, 1H), -OCH3 at δ3.83 (s, 6 H) and δ3.71 (s,3 H) (Figure
29B).
DLS showed the mean particle size of P-SMART was 71.51±0.47 nm (PDI:
0.055 ± 0.011) (Figure 29C). Naked SMART-OH was stable under alkaline
hydrolysis condition and drug payload of conjugated SMART-OH was determined
by HPLC analysis as 14.3±2.8 % (w/w).
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4.3.4 PH dependent drug release
In vitro drug release studies were carried out in PBS at pH 7.4 and acetate
buffer at pH 6.5 to simulate drug release in blood and tumor environment. PSMART showed a slow but sustained release of SMART-OH. There was no
noticeable initial burst release at the different pH and no significant drug release
at neutral conditions afterwards. At pH 6.5, the liberation of SMART-OH from PSMART was accelerated as expected due to the increased cleavage of ester
linkages known to occur in an acidic or basic environment. After five days, more
than 25% of SMART-OH was released at pH 6.5, but only 15% of SMART-OH at
pH 7.4 (Figure 29D).
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Figure 29. Synthesis and characterization of mPEG-b-PCC-g-SMART-g-DC (PSMART). A) Synthetic scheme of P-SMART. B) 1H NMR (500 MHz, DMSO-d6)
spectrum of P-SMART. C) Particle size distribution of P-SMART by dynamic light
scattering (DLS). The mean particle size of P-SMART was 71.51±0.47 nm. D) In vitro
drug release profile of P-SMART. Concentration of released SMART-OH at each time
point was measured by HPLC and drug release profiles were represented as the mean
± SEM (n=3). P-SMART showed a slow but sustained release of SMART-OH at neutral
and acidic condition.

4.3.5 Anticancer activity
We determined the anticancer activity of P-SMART as well as parent drug
SMART-OH on A375 and B16-F10 cells for 72 h. Due to the slow release of
SMART-OH from the polymer conjugates, the IC50 of P-SMART increased to 0.75
μM in two cell lines while IC50 of SMART-OH was 75 nM in A375 cells and 150 nM
in B16-F10 cells. P-SMART effectively killed 80% of melanoma cells at 2 μM parent
drug equivalent dose (Figure 30A).
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4.3.6 Inhibition of colony formation
The inhibitory effect of SMART-OH and P-SMART on tumorigenic potential
in melanoma cells was determined by colony formation assay. The parent drug
SMART-OH greatly reduced colony formation compared with the control group in
both cell lines. Meanwhile, long-term treatment of P-SMART allowed much amount
of conjugated drug to be released from the conjugate and then expose to
melanoma cells, which resulted in significant anti-proliferative effect. Treatment of
A375 with P-SMART at a dose of 75 nM reduced colony formation by 94.5%
compared to the control and treatment of B16-F10 cells with 200 nM P-SMART
reduced colony formation by 79%. The doses of P-SMART in this assay were far
below the IC50 of P-SMART in cytotoxicity assay (Figure 30B).
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Figure 30. Cytotoxicity and colony formation assay. A) Cytotoxicity of SMART-OH
and P-SMART was determined in A375 and B16-F10 cells for 72 h. The IC50 of PSMART was 0.75 μM in two cell lines. B) To determine colony formation of melanoma
cells, 250 cells per well were seeded to 6-well culture plates. At 24 h, drug formulations
were added and at 7 days, cell colonies were fixed, stained and counted. The longterm treatment of P-SMART resulted in significant anti-proliferative effect. Data
represented as the mean ± SEM (n=3). *p<0.05, **p<0.01 compared to Control.

We also determined the inhibitory effect of SMART-OH and P-SMART on
cell invasion using B16-F10 cells. At a dose of 0.5 μM, both parent drug and
prodrug showed effective inhibition of cell invasion. Treatment of SMART-OH
suppressed 87% of cell invasion while the ability of P-SMART to prevent cell
invasion was slightly less with 73% of cell invasion blocked at 24 h (Figure 31).
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Figure 31. Cell invasion assay. B16-F10 cells were treated with either SMART-OH
(0.5 μM) or P-SMART (0.5 μM, equivalent to parent drug) and allowed to invade
through Matrigel for 24 h. Results were shown as mean number of invaded cells ±
SEM (n=3). Treatment of SMART-OH suppressed 87% of cell invasion and P-SMART
blocked 73% of cell invasion. *p<0.05, **p<0.01 compared to Control.

4.3.7 Effect of P-SMART on cell cycle and apoptosis
The effect of P-SMART on cell cycle and apoptosis was determined by PIstaining using A375 and B16-F10 cells. There was observable G2/M phase arrest
after treatment of these cells with P-SMART for 48 h and the % of cells in G2/M
phase was augmented in a dose dependent manner. Specifically, the number of
A375 cells increased from 14.9% in the control group to 19.1% with 1 μM of PSMART and to 39.0% with 1.5 μM of P-SMART (Figure 32A). Similarly, the % of
B16-F10 cells increased from 11.3% in the control group to 22.9% with 1.5 μM of
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P-SMART and to 53.0% with 2 μM of P-SMART (Figure 32B). In addition, the
number of A375 cells in sub-G1 phase elevated from 0.04% in the control group
to 24.0% with 1.5 μM of P-SMART (Figure 32A). The number of B16-F10 cells in
sub-G1 phase increased from 5.2% in the control group to 28.3% with 2 μM of PSMART (Figure 32B). The accumulation of cell population in sub-G1 phase
indicated that apoptotic cells significantly increased after P-SMART treatment.

Figure 32. Cell cycle analysis and apoptosis of P-SMART. Cells were treated with
P-SMART for 48 h, stained with propidium iodide (PI), and analyzed on a flow
cytometer. A) A375. B) B16F10. Results were expressed as the mean ± SEM (n=3).
The percent of cells in G2/M phase and sub-G1 phase was augmented in a dose
dependent manner after treatment with P-SMART.
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4.3.8 In vivo efficacy in B16-F10 lung metastatic mouse model
We successfully established a metastatic melanoma model in 8-week-old
female C57BL/6 albino mice by injecting B16-F10-luc cells via tail vein. At day 10,
all mice were imaged for luciferase bioluminescence to determine the tumor growth
rate. The mice whose bioluminescent radiance reached 105 were randomized into
three groups: 1) control, 2) SMART-OH and 3) P-SMART. All treatments were
administered intravenously at the equivalent dose of 20 mg/kg SMART-OH. Both
parent drug and prodrug groups showed inhibition of tumor growth compared with
the control group. Significantly higher tumor growth inhibition was observed in the
group treated with P-SMART compared with the group treated with SMART-OH
(Figure 33 and 34A).

Figure 33. In vivo representative bioluminescent images at first day and last
day of treatments. Mice (n=5) from Control (saline), SMART-OH and P-SMART
groups were taken bioluminescent images every alternate day during the treatment.
Images of four mice from each group were shown.
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In addition, treatment with P-SMART significantly reduced the number of
lung tumor nodules compared to the control and SMART-OH groups (Figure 34BC). The survival study showed that the median survival was 28 days in the control
group and 31 days in the SMART-OH group. The median survival was significantly
prolonged (38 days) when mice were treated with P-SMART (Figure 34D).

Figure 34. In vivo efficacy of SMART-OH and P-SMART in B16-F10 lung
metastatic animal model. Mice received saline, 20 mg/kg SMART-OH or 20 mg/kg
P-SMART intravenously once every three days for a total of five times when the
radiance of tumor had reached 105 (day 10 after tumor implantation). A) Radiance
intensity plot of all groups was measured from day 10 to day 24. Data represented as
the mean ± SEM (n=5). B) Representative tumors of each group were excised after
sacrificing the mice at the end of the efficacy study. Significantly higher tumor growth
inhibition and less number of lung tumor nodules was observed in the group treated
with P-SMART compared to SMART-OH treated group. C) The weight of mouse lungs
from each group was measured at the end of the study. D) Survival analysis of control
group, SMART-OH group and P-SMART group. The median survival was 31 days in
SMART-OH group and 38 days in P-SMART group while in control group median
survival was 28 days.
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Hematoxylin and eosin (H&E) stain of lung tissues confirmed the extensive
metastasis throughout the lung lobe in the control group and the inhibition of
metastasis and proliferation of tumor cells in the treated groups. As compared with
the control and parent drug groups, the lung samples from P-SMART treated group
exhibited alveolar lumen with limited mass of metastatic cells (Figure 35A).
Furthermore, cleaved caspase-3 stain indicated the induction of significant
apoptosis by treatment of P-SMART compared to the treatment of SMART-OH
(Figure 35B). Additionally, the chronic toxicities of these treatments were also
evaluated by histological analysis of the major organs (Figure 35C). No obvious
histological changes were observed in the livers, spleens, kidneys and hearts from
all the treated groups, which suggested that mice tolerated all treatments well.
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Figure 35. Analysis of lung samples by hematoxylin and eosin (H&E), Caspase
3 stain and analysis of major organs by H&E stain. Lung samples from control,
SMART-OH and P-SMART treated groups were excised, fixed and immunostained for
A) H&E and B) Caspase 3. In control group the metastasis was throughout the lung
lobe but in the treated groups the metastasis and proliferation of tumor cells was
inhibited. Cleaved caspase-3 stain indicated significant the induction of apoptosis by
P-SMART. C) Organ samples from three groups were excised, fixed and stained for
H&E. No obvious histological changes were observed in the livers, spleens, kidneys
and hearts from all the treated groups.
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4.4 DISCUSSION
Conventional therapies of melanoma such as dacarbazine (DTIC) and
combination of paclitaxel and carboplatin are small molecular weight drugs, which
are rapidly eliminated from the circulation, requiring frequent dosing, leading to
increased risk of side effects. From a clinical standpoint, many anticancer agents
that are hydrophobic require appropriate drug delivery system to help them reach
tumors after systemic administration. To solve this problem, hydrophobic drugs are
encapsulated into liposomes, nanoparticles and micelles. However, physical
encapsulation into these nanoparticulate systems usually results in fast drug
release with burst effect. This means higher initial drug loading is needed because
most drugs should ideally be released at the disease site to reduce their adverse
effects. In contrast, chemical conjugation of drugs to polymers or lipids prevents
immediate drug release during the transportation of polymer-drug conjugates and
provides long-term sustained drug release (Figure 29D). Therefore, conjugation
of a drug to the polymer prolongs drug circulation and enhances therapeutic
efficacy. So far polymer-drug conjugates with linear backbone have undergone
clinical

evaluation,

such

as

poly(ethylene

glycol)

(PEG),

poly[N-(2-

hydroxypropyl)methacrylamide] (PHPMA) copolymers, dextran and poly(glutamic
acid) (PGA) [61-63].
We previously physically encapsulated SMART-100 into poly(ethylene
glycol)-b-poly(D,L-lactide) (PEG-PLA) micelles by film dispersion.[98] As expected,
drug loading in these physically drug encapsulated micelles was 1.5%. To increase
drug loading, in previous studies we conjugated gemcitabine or paclitaxel to
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mPEG-b-PCC, and in the current study we conjugated a novel microtubule inhibitor,
SMART-OH, to the copolymer.
PEG was used as a hydrophilic block for synthesizing methoxy-poly
(ethylene

glycol)-block-poly

(2-methyl-2-carboxyl-propylene

carbonate-graft-

dodecanol) copolymer. To form micelles, we need to maintain a delicate balance
between hydrophilic and lipophilic components of the copolymer. Since the
molecular weight of our polymer is in the range of 10,000-11,000 Da, we chose
PEG of 5000 Da for synthesizing this polymer before conjugating our drug SMARTOH. If we use PEG of 2,000 Da, we could not have conjugated SMART-OH as
much as what we have done in this work, otherwise no micelles could be formed.
This PEG length helps us maintain higher HLB easily and allows us conjugating
large amount of SMART-OH. The attachment of dodecanol (DC) also enhanced
requisite hydrophobicity to form micelles of polymer-drug conjugate. Our polymerdrug conjugation system offers the following distinct advantages: a) PEG corona
on the polymer imparts stealth property; b) conjugation ensures in vivo stability and
no premature drug release in the circulation; c) small size of this conjugate
facilitates the EPR effect to maximize drug delivery to the tumor. Therefore, these
polymer-drug conjugate showed increased stability and antitumor effect compared
to parent drugs.
Microtubule targeting agents that alter microtubule dynamics have been
developed as anticancer drugs for more than several decades, and they have
achieved exceptional clinical success acting as essential roles in combination
therapy and adjuvant therapy [102-104]. These compounds are currently classified
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as microtubule stabilizers and destabilizers based on their function on microtubule
mass at high concentrations. Stabilizing agents such as taxanes, epothilones,
discodermolide, laulimalide, peloruside A, etc., enhance tubulin polymerization
and block microtubule dynamics [105]. On the other hand, microtubuledestabilizing agents suppress tubulin polymerization and can be further
characterized into two groups: vinca-domain binders and colchicine-domain
binders. Although the wide application of microtubule inhibitors is observed, there
is urgent need to overcome several emerging challenges including drug-resistance
and neurotoxicity [106,107].
In this study, we synthesized a novel microtubule destabilizer, SMART-OH,
with a hydroxyl group for conjugation with the copolymer (Figure 27). Molecular
modeling suggested strong interactions between SMART-OH and the tubulin
dimer, with the phenolic moiety forming a strong hydrogen bond interaction to
Val315 in tubulin, in addition to the other two hydrogen bonds and hydrophobic
interactions between SMART-OH and tubulin dimer (Figure 28A). Further, in vitro
tubulin polymerization assay confirmed experimentally that SMART-OH effectively
disrupted tubulin polymerization, serving as a potent microtubule-targeting agent
(Figure 28B). It is also known that microtubule-targeting agents suppress
microtubule dynamics leading to cell cycle arrest at the mitotic phase. In cell cycle
analysis, cells were arrested in G2/M phase after treatment with P-SMART (Figure
32), which confirmed that the mechanism of action of P-SMART was through
destabilization of microtubules. Treatment of P-SMART also resulted in cell
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accumulation in sub-G1 phase indicating cell apoptosis and DNA damage was
induced by P-SMART treatment.
In addition to its effects on microtubules, P-SMART demonstrated other
anticancer activities in cytotoxicity, colony formation and cell invasion assays. As
expected, P-SMART resulted in lower toxicity in A375 and B16-F10 cells when
compared with the parent drug SMART-OH in a dose dependent manner. The IC50
of P-SMART was 0.75 μM in both cell lines which was about 10-fold higher than
SMART-OH in A375 cells and 4-fold higher in B16-F10 cells (Figure 30A). This
finding is in good agreement with previous reports suggesting that conjugated
anticancer drugs have higher IC50 than their corresponding parent drugs due to
slow drug release kinetics [108,109]. Unlike cytotoxicity assay, SMART-OH and PSMART showed nearly equivalent activity in the colony formation assays (Figure
30B) likely due to the 7-day incubation period, which provided P-SMART with more
time for cellular uptake and drug release. Therefore, the difference in anticancer
effect between free drug and conjugated drug was reduced and this result
demonstrated that the potency of SMART-OH was maintained after conjugation.
As discussed above, melanoma has high metastatic propensity and easily
metastasizes to other organs. Thus, we did a transwell invasion assay to determine
whether SMART-OH and P-SMART can impede the migratory potential and the
invasive property of melanoma cells. Both SMART-OH and P-SMART showed
significant cell invasion inhibition (Figure 31), which confirmed this drug had good
anti-metastatic properties in vitro.
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To investigate in vivo efficacy of SMART-OH and P-SMART, B16-F10-luc
cells were selected to establish a metastatic model in C57BL/6 albino mice. We
chose 20 mg/kg as the dose of SMART-OH and P-SMART based on our previous
studies. We plan to do dose escalation studies and will report in our future
publication. Both treated groups exhibited promising tumor inhibitory results.
However, P-SMART treatment showed further enhanced reduction in tumor
growth rate and tumor size compared with SMART-OH treatment (Figures 33-34).
Apart from tumor growth suppression, P-SMART also extended mouse survival
compared to other groups. In addition, a significantly lower burden of metastatic
cells and increased level of apoptotic cells were found in P-SMART group. H&E
stain of vital organs demonstrated our formulation carrying P-SMART was well
tolerated, as other healthy organs did not show obvious histological changes after
treatments (Figure 35). This is in agreement with our recent report indicating that
our biodegradable copolymer mPEG-b-PCC as the backbone of delivery system
has less toxicity and good safety [84].
4.5 CONCLUSION
We have synthesized a novel microtubule destabilizer SMART-OH and its
corresponding polymer-drug conjugate P-SMART. Our results demonstrate that
SMART-OH binds to microtubules and suppresses tubulin polymerization. Both
SMART-OH and P-SMART inhibit in vitro proliferation and invasion of melanoma
cells. When tested in vivo, P-SMART treatment shows increased anticancer
efficacy in a melanoma model with lung metastases compared to the control and
SMART-OH treatment. Future work to fight with metastatic melanoma will focus
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on improving the potency of novel microtubule inhibitors and optimization of our
delivery system by including targeting moieties.
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CHAPTER 5 SUMMARY AND FUTURE DIRECTIONS

5.1 SUMMARY
Prostate cancer is one of the most common cancer types and the second
leading cause of cancer-related death in American men. Although several
hormone therapies (or androgen deprivation therapy) as first line treatments are
effective for prostate cancer in early stage, the shrunken tumors might become
androgen-independent after 18 to 24 month treatment leading to aggressive and
metastatic forms of prostate cancer, also known as hormone refractory prostate
cancer (HRPC). Taxane (docetaxel and paclitaxel), used as chemotherapy, is one
of the standard therapies for HRPC. These anticancer agents have shown
significant efficacy at initial period of chemotherapy, however, the long-term
efficacy is limited and patients will suffer from relapse owing to the development of
chemoresistance.
One notable cellular mechanism behind chemoresistance is related to the
presence of cancer stem cells (CSCs). CSCs, a rare and distinct subset of cancer
cells, have stem-cell-like properties such as self-renewal/differentiation, and
tumorigenic potentials, which are responsible for cancer initiation, maintenance
and relapse. The birth of cancer-stem-cell theory can be traced back to 1994. John
Dick, a Canadian scientist, strikingly identified leukemia stem cell in human
leukemia and inaugurated a new era of cancer research. With decades of further
development, it has been established that CSCs are found in many other types of
cancer including breast, ovary, prostate, pancreas, colon cancer and melanoma.
A growing body of evidence suggests that several molecular signaling pathways such as
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Sonic Hedgehog (Hh) signaling, Notch signaling and Wnt/β-Catenin signaling mainly
involve in the initiation and development of CSCs. Therefore, in Chapter 2 and 3 we

studied the combination therapy of microtubule inhibitor (paclitaxel or QW-296)
and Hh signaling inhibitor (Cyclopamine or MDB5) to overcome drug resistance
and improve the therapeutic effect of chemoresistant prostate cancer. Since both
tubulin inhibitors and Hh signaling inhibitors are highly hydrophobic, we also
developed PEG-based polymeric drug conjugates or polymeric micelles to deliver
these anticancer drugs and enhance therapeutic efficacy. Our results indicated
that the combination formulations could synergistically work together with different
mechanisms of action and suppress chemoresistant prostate tumor growth in vitro
as well as in orthotopic mouse model.
Melanoma originated from melanocytes is the most aggressive type of skin
cancer. It has high potential to metastasize through lymph nodes to the distant
sites of the body, especially the lungs, liver and brain. Systemic chemotherapy
remains the mainstay of its treatment; however, multidrug resistance (MDR) and
dose limiting toxicity restrict the efficacy of current chemotherapeutic drugs. We
recently synthesize a novel microtubule destabilizer, substituted methoxybenzoylary-thiazole (SMART-100) and it can effectively circumvent MDR that hinders the
clinical efficacy of existing tubulin inhibitors. Nevertheless, poor water solubility of
SMART-100 requires co-solvent delivery for its systemic administration, which
associates with toxicity to liver and kidney, hemolysis and peripheral neuropathies.
Therefore, in Chapter 4, to solve this problem and prolong circulation of this small
molecule, we developed methoxy-poly (ethylene glycol)-block-poly (2-methyl-2carboxyl-propylene carbonate-graft-SMART-graft-dodecanol) (P-SMART) with
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high drug payload of SMART. This polymer-drug conjugate self-assembled into
micelles with small particle size and the release of SMART was slow but at
appreciable rate. Similar with its parent drug, P-SMART killed 60-70% of A375
cells and B16-F10 cells at 1 µM of equivalent concentration of SMART and
arrested cell cycle in G2/M phase. In addition, P-SMART significantly suppressed
colony formation and cell invasion of melanoma cells. We established lung
metastatic melanoma in C57/BL6 albino mice by injecting B16-F10-luc through tail
vein. During the treatments, there was maximum inhibition of tumor growth in PSMART group compared with control group and parent drug group. In conclusion,
this novel polymer-microtubule inhibitor conjugate P-SMART has the potential to
treat lung metastasis melanoma.
5.2 FUTURE DIRECTIONS
The preliminary findings reported in the prostate cancer projects and
melanoma project confirmed that the combination strategy or the novel tubulin
destabilizer had the potential to treat chemoresistant prostate cancer or metastatic
melanoma. The PEG-based polymeric formulations could promote the delivery
efficiency of these anticancer agents to the tumor sites leading to enhanced
therapeutic efficacy compared with their corresponding parent drugs. However,
from a perspective of clinical translation, our current polymeric delivery platform
could be improved from the following aspects.
First, it is known that nano-sized agents could preferentially leak into tumor
sites through permeable tumor vasculature; nevertheless, the EPR effects as
known as passive targeting are relatively moderate and at the same time a small
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portion of drugs can also extravasate into normal tissues. Therefore, in the future
we will attach targeting moieties such as peptides or antibodies to the polymeric
platform to develop a specific active-targeting drug delivery system, which can
reduce off-target delivery and release more anticancer drugs at the site of action.
Furthermore, besides targeting efficiency, the drug release profile is another
limiting factor for therapeutic efficacy, which suggests the composition of
formulation can be designed to release the drug according to the tumor
microenvironment or the therapeutic needs. Since the pH of tumor site is usually
acidic, in future studies we will modify polymer components to be sensitive to acidic
environment allowing pH-triggered drug release.
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